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Abstract
Purpose: The currently held mechanistic understanding of microsomal cytochrome P450s (CYPs) seeks that diverse
drug molecules bind within the deep-seated distal heme pocket and subsequently react at the heme centre. To
explain a bevy of experimental observations and meta-analyses, we indulge a hypothesis that involves a “diffusible
radical mediated” mechanism. This new hypothesis posits that many substrates could also bind at alternate loci on/
within the enzyme and be reacted without the pertinent moiety accessing a bonding proximity to the purported
catalytic Fe-O enzyme intermediate.
Methods: Through blind and heme-distal pocket centered dockings of various substrates and non-substrates (drug
molecules of diverse sizes, classes, topographies etc.) of microsomal CYPs, we explored the possibility of access of
substrates via the distal channels, its binding energies, docking orientations, distance of reactive moieties (or molecule
per se) to/from the heme centre, etc. We investigated specific cases like- (a) large drug molecules as substrates,
(b) classical marker drug substrates, (c) class of drugs as substrates (Sartans, Statins etc.), (d) substrate preferences
between related and unrelated CYPs, (e) man-made site-directed mutants’ and naturally occurring mutants’ reactivity
and metabolic disposition, (f) drug-drug interactions, (g) overall affinities of drug substrate versus oxidized product, (h)
meta-analysis of in silico versus experimental binding constants and reaction/residence times etc.
Results: It was found that heme-centered dockings of the substrate/modulator drug molecules with the available CYP
crystal structures gave poor docking geometries and distances from Fe-heme centre. In conjunction with several other
arguments, the findings discount the relevance of erstwhile hypothesis in many CYP systems. Consequently, the newly
proposed hypothesis is deemed a viable alternate, as it satisfies Occam’s razor.
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Conclusions: The new proposal affords expanded scope for explaining the mechanism, kinetics and overall
phenomenology of CYP mediated drug metabolism. It is now understood that the heme-iron and the hydrophobic
distal pocket of CYPs serve primarily to stabilize the reactive intermediate (diffusible radical) and the surface or crypts of
the apoprotein bind to the xenobiotic substrate (and in some cases, the heme distal pocket could also serve the latter
function). Thus, CYPs enhance reaction rates and selectivity/specificity via a hitherto unrecognized modality.
Keywords: Cytochrome P450, Heme-enzymes, Mechanism, Substrate binding
Background
The cytochrome P450 (CYP) family of enzymes possesses
the heme-thiolate functionality and they mediate the phase
I metabolism of a vast majority of drugs and xenobiotics in
most animals, including man (Testa 1995). Many of these
reactions are known to be regiospecific and some of them
are even enantioselective (Martinez and Stewart 2000).
Since the hydroxylation of several non-activated substrates
are not noted with the more commonly found heme-
histidylate proteins, CYPs’ catalytic mechanism called for a
defined and selective process, which the protein’s "active
site" could afford. Therefore, the fundamental step in the
catalytic mechanism invoked the formation of high poten-
tial intermediate(s) centered at the heme-thiolate moiety,
involving an iron - oxygen species (Ortiz de Montellano
2015; Meunier et al. 2004; Denisov et al. 2005; Volz et al.
2002). This proposal was along the lines of a two-electron
deficient catalytic species identified as Compound I
observed in heme peroxidases (Raven and Dunford 2015).
Thereafter, the substrate’s interaction with this enzyme
active intermediate is understood to occur by an ‘oxygen-
rebound’ mechanism (Groves 1985). As per the prevailing
understanding, the formation of this catalytic CYP inter-
mediate solicits a highly fastidious, multi-step, ordered
process involving termolecular complexations of CYPs with
cytochrome P450 reductase (CPR), cytochrome b5 (Cyt. b5),
substrate, molecular oxygen etc. (Guengerich and Isin
2008). Such a catalytic cycle requires that the diverse
substrates (herein considered as the final oxygen atom
acceptor) bind to a given distal heme pocket of a CYP at
the very first step (and stay bound till the very end), to
induce a redox potential change of the heme-iron for the
overall cycle (for protein-protein electron transfer, substrate
hydroxylation and superoxide/peroxide/water production)
to be feasible (Guengerich and Isin 2008). Therefore, the
prevailing CYP catalytic mechanism obligatorily espouses a
high-affinity binding and positioning of the diverse sub-
strates at a favorable locus within the distal heme pocket
(also known as the “active site”). When the substrate gets
converted to the product, the latter is supposed to lose af-
finity for the enzyme and hence, it detaches and diffuses
out of the ‘active site’.
“Lock & Key” (Fischer 1894) and “Induced Fit” (Kosh-
land 1958) models are routinely used to explain enzyme
activity. The currently conceived CYP reaction model em-
ploys a version of the latter scheme to explain the sub-
strate selectivity and the former scheme is invoked to
explain reaction specificity. It is suggested that the F and
G loops/helices are considerably flexible across all CYPs
(Poulos and Johnson 2005; Narasimhulu 2010). There is
also crystallographic evidence to suggest that CYPs have
“closed” and “open” conformations (Poulos 2014). This
finding is taken to support the suggestion that a CYP can
open up for a substrate and then close itself upon the
substrate after its presentation, thereby “committing it to
catalysis” (Lu 1998). The erstwhile hypothetical paradigm
is challenged by the fact that CYPs are typically character-
ized by broad selectivity/specificity. That is, a given CYP
enzyme might catalyze the metabolism of a diverse array
of substrates of various topographies and dimensions
(containing functionally distinct moieties), at multiple loci
of the given drug molecule (Sugimoto and Shiro 2012;
Ekins et al. 1999; Lewis and Dickins 2002). The crystal
structures of major CYPs are known today, complexed
with some of their known substrates (Williams et al. 2003;
Wester et al. 2004; Ekroos and Sjögren 2006; Sevrioukova
and Poulos 2012). In many of these systems, the substrate
is positioned too far from the heme-centre for a direct
attack at the reactive moiety (Ekroos and Sjögren 2006).
Also, it is difficult to visualize why/how a constrained
active site of CYP would not give an enantioselective or
regioselective reaction for some large molecules. Further,
it is intriguing how some of the most sterically obstructed
sites within a given substrate is hydroxylated when there
are other favorable loci available within the very substrate
molecule (given the understanding that Compound I, the
enzymic reactive intermediate, is supposedly a high poten-
tial species). Therefore, some spatial considerations appar-
ently challenge the hitherto available ‘high
affinity substrate binding at active site’ theory.
A few years back, we had proposed alternative modalities
of substrate interactions for the heme-thiolate (extracellular,
fungal) enzyme, chloroperoxidase (Manoj 2006; Manoj and
Hager 2008). Recently, we have also solved several aspects
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of heme-enzyme activations, inhibitions and other kin-
etic observations using appropriate biochemical experi-
mental controls and logical deductions (Gideon et al.
2012; Manoj et al. 2010a; Manoj et al. 2010b; Parashar
et al. 2014; Parashar and Manoj 2012). In these works,
we went beyond the purely classical substrate-binding
based Michaelis-Menten kinetics. We wondered if these
ideas would be relevant in CYP-drug metabolism
mechanistic chemistry. Molecular docking and theoret-
ical predictions (based on dataset training/modeling/
dynamic simulations) are an efficient and accepted way
of understanding structure-function correlations (Yuriev
et al. 2015; Cross and Cruciani 2010; Scotti et al. 2015;
Hlavica 2015; Olsen et al. 2015; Cruciani et al. 2005;
Mudra et al. 2011; Kirchmair et al. 2012; Mendieta-
Wejebe et al. 2011; Lewis and Ito 2010). Therefore, we
undertook an in silico exploration study of the available
crystal structures of human microsomal CYPs and probed
its “static” docking interactions with diverse “flexible”
substrate drug molecules.
Methods
Dimensions of small molecules
Dimensions of the substrates were calculated using
MarvinSketch 6.2.0 (http://www.chemaxon.com). The
option of geometrical descriptors was used for this purpose.
Crystal structures of proteins employed
Table 1 details the names and references for the pdb files
employed in the current study.
Cavity analysis
Crystal structures of CYPs obtained from RCSB PDB
were visualized using PyMol 1.3 (DeLano 2002) and
CAVER 3.0.1 (as a plugin in PyMol) (Chovancova et al.
2012) was used to calculate and visualize the tunnels. All
molecules were analysed with default parameters except
for the minimum probe radius (cut off diameter) which
is mentioned against the corresponding entry (Table 2).
From the output files, length, curvature and bottleneck
data of the proteins were obtained. Substrates from sub-
strate bound protein PDB structure were deleted using
Chimera 1.7 (Pettersen et al. 2004) to obtain open and
free tunnels.
Docking
Crystal structures of CYPs were obtained from RCSB
PDB and used as rigid large molecule receptors. Struc-
tures of all the substrates used were obtained from
PubChem and energy minimized using Chimera 1.7.
Protein and ligand molecules were primed for docking
using AutoDock tools (MGL Tools 1.5.4) and docked by
AutoDock 4.2 (Morris et al. 2009) to explore the binding
sites of ligands on the protein. Blind docking was carried
out with a grid covering the whole protein for 100 runs
to identify putative and unorthodox binding sites inside
and outside the active site (represented as Blind Dock-
ing or GridB). Refined docking was carried out within
well-demarcated grid on the heme active site region (the
hydrophobic pocket above heme) of a given protein with
each ligand for 100 runs (represented as Centred Dock-
ing or GridC). PyMol 1.3 and MarvinView 6.2.0 was used
to visualize the output. The conformers or clusters with
the lowest binding energy for a given ligand were deter-
mined. In the two ligand scenarios of drug interactions
study, we used CYPs pre-docked with a ligand as a rigid
protein (competitive inhibition for the Enzyme, E; since
we thought it was unlikely that a bevy of molecules could
have the lesser probable ES + I binding) and docked it
against a flexible substrate. RMSD values were calculated
using Chimera 1.7 and it was noted that ProFit also gave
similar results.
Homology modelling
For genetic predisposition of drugs study, three dimen-
sional models of single amino acid substitution mutation
containing CYPs were generated using SWISS – MODEL
(Arnold et al. 2006) against the respective wild type pro-
tein structures as templates. The amino acid sequence
containing the mutated amino acid was given as input and
searched for templates. From the results, the respective
Table 1 Names and references for enzyme crystal structures
explored in the current study
S.
No.
Enzyme PDB identity Reference(s)
1. CYP1A2 2HI4 (Sansen et al. 2007)
2. CYP2A6 1Z11 (Yano et al. 2005)
3. CYP2C9 1R9O, 1OG2,
4NZ2
(Wester et al. 2004;
Williams et al. 2003;
Brändén et al. 2014)
4. CYP2C19 4GQS (Reynald et al. 2012)
5. CYP2D6 2F9Q (Rowland et al. 2006)
6. CYP2E1 3E6I (Porubsky et al. 2008)
7. CYP3A4 1TQN, 3UA1,
2J0D, 2V0M,
4K9T, 3TJS





8. CPO 2CPO (Sundaramoorthy et al.
1995)
9. P450cam 2CPP (Poulos et al. 1987)
10. FAB 1GAF (Patten et al. 1996)
11. Estrogen
receptor
3ERT (Shiau et al. 1998)
12. Cellobiohydrolase 1DY4 (Ståhlberg et al. 2001)
13. Avidin 2AVI (Livnah et al. 1993)
14. Glucokinase 3IDH (Petit et al. 2011)
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Table 2 Cavity analysis of CYPs by PyMol/CAVER
Enzyme (PDB) Channels by Pymol
[with one H2O radius]
Channels by CAVER
(cut-off diam. in Å)
Lengtha (Å) Vol. (Å3) Curvature a Bottleneck Dia.a (Å) Classical substrate
dimensions (Å/Å3)
Amino acids lining the bottlenecka
CYP 1A2 (2HI4) Nil 3 (1.8) 21.6 406 1.19 1.9 Theophylin 4.81, 4.44; 175 F256, N257, Q258, L116, I117, T118,
D119, F260, L261
CYP 2A6 (1Z11) 1 + 1 (proximal) 7 (1.8), 1 (2) 18.0 222 1.54 1.99 Coumarin 4.96, 3.68; 127 G102, E103, F118, Q104, D108, R101,
A371, A105
CYP 2C9 (1R9O) 2 + 1 (proximal) 15 (1.8), 9 (2), 6 (2.2),
3 (2.6), 1 (3.4)
13.0 1457 1.25 3.4 Flurbiprofen 6.99, 3.81; 223 S209, I205, V479, E300, A477, E206,
S478, T304, L208
CYP 2D6 (2F9Q) 1 18 (1.8) 7.8 797 1.16 4.3 Bufuralol 7.36, 4.91; 267 F120, T309, V370, A305, L484, R374,
p373, V308, S304, G306, C443
CYP 2E1 (3E6I) Nil + 1 (Proximal) 10 (1.8), 3 (2), 2(2.2) 21.9 267 (190 + 77) 1.31 2.28 Chlorzoxazone 5.42, 3.71; 144.02 L368, V364, F478, N367, F207, G479,
L363
CYP 3A4 (1TQN) 3 14 (1.8), 4(2), 2 (2.4) 12.7 1508 1.21 2.42 Testosterone 6.67, 4.15; 292.55 Q484, L482, E308, R212, S312, L211
CPO (2CPO) 1 2(1.8), 1 (2.6) 8.7 na 1.14 3.16 CBMS 5.15, 3.12; 118.2 F186, F103, E183, A71, O179, V182
P450cam (2CPP) Nil 5 (1.8) 25.8 na 1.34 1.98 Camphor 4.19, 3.93; 160.86 V247, T181, M184, L180, L200, D182,
F98, G243, T185
aDetails of highest ranked tunnel in terms of priority. Minimum probe diameter−1.8 Å. Dim./vol. - Maximal projection radius (Å), Minimal projection radius (Å); Van der Waals volume (Å3) na- not available; Curvature =
length/distance, where length is the length of the tunnel (distance from the calculation starting point to the tunnel ending point calculated along the tunnel axis) and distance is the shortest possible distance












wild type protein structure with maximum coverage and
identity was chosen for modelling. The output was saved
as a PDB file and used for docking, as described earlier.
Results
Distal heme active site cavities/tunnels of some CYPs and
interactions of the enzyme with substrates
Table 2 details the physical dimensions of- active site
cavity, classical substrates and the tunnels from distal
heme centre leading to the solvent continuum. Investi-
gation with PyMol showed that the highly versatile
CYP3A4 has three channels leading to the distal active
site cavity (followed by 2 channels for CYP2C9, another
versatile liver microsomal CYP), more than any of the
other CYPs. With CAVER, all major CYPs (with
relatively higher substrate diversities and greater roles in
overall contributions towards drug metabolism, as exem-
plified by 3A4, 2C9, 2D6 and 2E1) gave 10–18 channels
(with a water molecule’s diameter as the limiting con-
straint). Many of these tunnels were relatively long,
twisted or too narrow. One would imagine that such
channels would not serve significant roles in the move-
ment of a bulky substrate molecule to the distal heme
centre. The amino acids lining the bottleneck of the
active site channels were seen to vary significantly across
the diverse CYPs. This might suggest little commonality
in mechanisms relating to opening/closing of the chan-
nels or F/G helices or loops.
Table 3 shows the data for the influence of substrate
molecule on the tunnels leading to the distal active site in
two prominent CYPs. That is- we probed to see what hap-
pens to the channels in the “induced fit” substrate-bound
CYPs. In CYP 3A4, when the substrate or inhibitor is
bound, no channels were available (for a water molecule
to enter the distal active site) (Sevrioukova and Poulos
2012). Comparison of the crystal structures of CYPs with-
out substrates/inhibitor with (i) crystal structure of CYP
bound with substrate/inhibitor and (ii) substrate deleted
from substrate-bound CYPs gave almost the same data as
that of the former. Similar amino acids are still seen and
the overall conformation is more or less retained. So, the
presence of the substrate does not overtly alter the native
structure of the protein for the two prominent micro-
somal CYPs, as seen from the analysis above. This finding
does not imply significant changes in tertiary structure via
an induced fit mechanism, as the erstwhile hypothesis
would necessitate to explain outcomes.
Table 4 shows the data for blind docking and "active-
site" grid-centred docking of several large drug molecule
substrates with their CYP counterparts. (The details of
molecular structure and reaction schema are given in
Additional file 1A, Figure A1A 1 &2.) The blind docking
and heme-pocket grid-centred docking gave different re-
sults. The first two entries, Trabectedin and Vinorelbine
are molecules that are metabolized by more than one
CYP. In both these cases, binding at the heme distal
pocket is not energetically favorable for CYP2E1. Also,
the substrate has a much higher volume than the heme
distal pocket of this CYP (Table 2). In heme distal site
centred docking, CYP2C9 has very little favorable bind-
ing energy, poor orientation and heme-Fe to reactive
moiety distance for Trabectedin. For both these mole-
cules, the binding energies were more favorable at alter-
nate locations on the protein for the CYPs (2E1 and
2C9), as evident with the data for blind-docking. For the
maverick CYP3A4, at least four substrates (Trabectedin,
Benzoxamino-rifamycin, Tacrolimus and Cyclosporin)
did not show a favorable binding energy with heme
distal pocket grid-centred docking, but the same substrates
showed spontaneous binding ability at other locations on
the protein. For CYP3A4, comparable (or slightly better)
binding energy was seen outside the heme distal pocket for
Erythromycin, Teniposide and Itraconazole (in comparison
to the active-site grid-centred docking). These substrates
gave a favorable binding at several loci on the protein sur-
face, as shown with the blind-docking data. In most of
CYP3A4 examples, the heme-pocket grid-centred docking
gave poor substrate presentation geometries with heme-Fe
to reactive moiety distance ranging ~ 5 to 22 Angstroms.
Considering the molecular dimensions of these substrates
vis a vis the heme-distal pocket dimensions (as shown in
Table 2), it is difficult to envision the parameters of spatial/
topographical recognition that subsequently lead to the
binding or positioning of such diverse large molecules in
the constrained heme distal pockets of the CYPs. A simple
analysis of the large substrate molecules (as exemplified in
1, 4, 11, 12, 16 etc. of Table 4) shows that the reaction locus
is many times on rather occluded positions (towards the
middle and not the ends/tips). Such reactive loci may be
accessed by the heme Fe-O species with a major opening
up of the protein or inversion of the active pocket, accom-
panied by significant conformational flexibility on the sub-
strate drug molecules. This would be a low probability
event when considering the experimental observation
(noted in protein-solution state) that a methyl substitution
on an adjacent carbon renders a heterocyclic nitrogen lone
pair ineffective from Type II coordination at the heme
centre (Jones et al. 2011).
Classical marker substrates and their interactions with CYPs
We selected a few well-known high affinity protein-
small molecule binding examples as control models of
enzyme-substrate binding. The results for these controls
are given in Table 5 (and the docked images are available
in Additional file 1A, Figure A1B 1–8). Only 3/8 of
the blind or centred docks showed RMSD values ≤ 2.5
Angstroms (with respect to the crystal structure).
However, a visual examination shows that in the
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Table 3 Effect of substrate on active site channels of CYPs
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N - Number of predicted tunnels; a - details given for channel with highest ranked priority












Table 4 Docking of very large substrates to CYPs
S.
No.
Substrate Enz. Reaction Dimension
/Vol. (Å/Å3)
Blind Docking Centred Docking Ref
Lowest Energy
(kcal/mol)
Distance (Å) Interactions Lowest Energy
(kcal/mol)








+29.90 5.8 LEU438 + (Vermeir et al. 2009;
Reid et al. 2002)





2E1 −2.23 25.9 GLN401
GLU402
LYS422
+1699.52 3.0 THR303 +









- (Kajita et al. 2000;
Topletz et al. 2013)
2E1 −3.06 30.1 LEU50 +369.73 13.2 THR303 - (Beulz‐Riché et al. 2005)
3 Tacrolimus 3A4 demethylation 9.48,
8.06;
787
−2.33 24.6 PRO107a +38.21 8.8 ARG105
ARG212
SER119












- (Mae et al. 1996)








- (Kelly et al. 1999;
Ohta et al. 2005)








- (Wang et al. 2000)











(+) (Relling et al. 1994;
Julsing et al. 2008)
7 Itraconazole 3A4 Hydroxylation 11.32,
6.73;
529




- (Isoherranen et al. 2004;
Templeton et al. 2008)











- (Dingemanse et al. 2002;
Chen et al. 2014)







- (Kassahun et al. 2005;
Katial et al. 1998)



























- (Klees et al. 2005;
Kharasch et al. 1997)










- (Kudo et al. 1999)
12 Bromoergocriptine 3A4 Hydroxylation 9.96,
6.10;
550




- (Wynalda and Wienkers
1997; Sevrioukova and
Poulos 2012)








- (Yamazaki et al. 1996)
14 Ritonavir 3A4 Demethylation 10.44,
7.54;
585
−1.26 26.9 LYS390 −3.58 19.5 SER312
GLN484
LEU483
- (Kumar et al. 1996)
Dimensions/volume - maximal projection radius (Å), minimal projection radius (Å); van der Waals volume (Å2)
Tacrolimus – 2C9 – GridC – 100th (last) ranked is positioned fully inside hydrophobic pocket with energy→ +46.14, Distance – 9.2 Å. (proved with repeat)
Itraconazole – 3A4 – GridB – The 3rd ranked (in the 2nd cluster has better presentation)→ 4.18 (10.2 Å)












majority of the cases, both blind and centred docking
identified the same crypt on the protein as the ligation
port (Additional file 1A, Figure A1B). The small mole-
cules bound in similar fashion, albeit the binding
energy being a higher value (that is, a higher negative
number) in the centred docking. A salient example is
presented in estrogen receptor binding to hydroxyta-
moxifen (Fig. 1). Therefore, the blind docking
approach may be considered as a valid methodology
for finding out putative binding sites on the protein
(Hetényi and van der Spoel 2006) other than the sup-
posed “active site of heme distal pocket”. (This consid-
eration, definitely, does not address the ‘dimensional
constraints’ aspect of channels being available for the
substrate to access the distal pocket and the dynamics of
protein “opening up” or “breathing” in solution state.)
It is known that many CYPs have marker substrates. (The
details of molecular structure and reaction schema are given
in Additional file 1A, Figure A1C.) Of the four substrates
and CYPs studied for active-site grid-centred docking
(Table 6), only two CYP-substrate combinations (2C9-Flur-
biprofen & 2D6-Bufuralol) afforded favorable presentation
and heme-Fe to substrate reactive moiety distance. This is
when many CYPs gave better binding energies or presenta-
tion at the active site with non-marker substrates. For
example, CYP3A4 gave better values for Flurbiprofen, than
its natural metabolizer, CYP2C9. Also, both CYP3A4 and
CYP2D6 gave better orientations with Chlorzoxazone (at
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6 P450cam - Camphor TYR96 −6.51 TYR96 2.42 −6.93 TYR96 2.50 2CPP 2.42
7 CYP2C9 - Flurbiprophen ASN204
ARG108
−5.85d ARG108 16.13 −6.59 ASN204
ARG108
5.06 1R9O 11.95







cData of 2nd cluster provided. Free energy of first cluster is−3.56 kcal/mol (0.11 kcal/mol higher)
dData of 4th ranked binding in the 1st ranked cluster. Lowest free energy is−5.86 kcal/mol (0.01 kcal/mol higher)
eValue obtained by comparing all the three- crystal structure, blind-docked and centred-docks
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comparable binding energies) than its natural catalyst
enzyme, CYP2E1. These findings indicate that the
selection or reaction process need not obligatorily
involve binding/catalysis centred in the heme distal
pocket alone.
Therefore, a detailed blind docking study was carried out
for eight substrates across six major CYPs. In blind docking
(Table 7), most of the classical substrates did not afford a
highly fruitful binding at the heme centre. Several drug
molecules afforded better binding or presentation at a non-
specific CYP heme-distal pocket. Therefore, with the erst-
while understanding, we are at a disadvantage to account
for the non-reactivity of these substrates with the “non-spe-
cific CYPs”. Further, interactions with key amino acids
(which could be an argument for specific molecular triggers
involved in an induced fit type of process) were not seen to
Table 6 Marker Substrates and CYPs – Distal heme pocket-centred docking
Substrate→ Flurbiprofen Bufuralol Chlorzoxazone Testosterone
Dim;Vol (Å/Å3)→ 6.99, 3.81; 223 7.36, 4.91; 267 5.42, 3.71; 144 6.67, 4.15; 293
2C9 (1R9O) X 4.5 15.2 3.1 9.2
E −6.64 −5.73 −4.63 −7.88
I ARG204 ARG108 LEU208 ALA297 LEU208
P + - + -
2D6 (2F9Q) X 4.8 4.3 3.2 10.2
E −5.81 −6.13 −5.37 −7.33
I PHE483 LEU484 GLU216a ALA305 ALA305 LEU213
P + + + -
2E1 (3E6I) X 9.3 6.8 8.2 8.4
E −2.13 −3.52 −5.49 +11.67
I PHE478 PHE116a ALA299 ALA299 THR303
P - + (+) -
3A4 (1TQN) X 3.3 6.5 5.0 10.0
E −8.03 −6.61 −5.64 −6.61
I GLU374 ARG375 ARG440 SER119 SER119 ARG212
P + + + -
Dimensions/volume - maximal projection radius (Å), minimal projection radius (Å); van der Waals volume (Å3); aneighboring amino acids provided, X – distance
between heme centre and reaction site (Å). E - lowest binding energy (kcal/mol), I – Interactions. - bad presentation, + good presentation, (+) moderate
presentation (Not optimal but not facing the opposite end either)
Fig. 1 Docking (blind and heme-distal pocket centred) of hydroxytamoxifen to estrogen receptor and comparison with the crystal structure. The RMSD
values are given in Table 5
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Table 7 Marker Substrates and CYPs – Blind docking
Substrate(CYP preference)→ Theophylin (1A2) Diclofenac (2C9) Warfarin (2C9) Flurbiprofen (2C9) Mephenytoin (2C19) Bufuralol (2D6) Chlorzoxazone (2E1) Testosterone (3A4)
Dim;Vol (Å/Å3)→ 4.93, 4.35; 147 6.00, 4.82; 240 6.54, 5.28; 277 6.99, 3.81; 223 5.66, 4.46; 201 7.36, 4.91; 267 5.42, 3.71; 144 6.67, 4.15; 293
1A2 (2HI4) X 7.0 32.3 24.1 21.1 32.0 32.4 4.7 20.0
















2C9 (1R9O) X 19.8 18.8 23.7 17.3 11.0 15.2 7.7 20.2
E −3.34 −6.15 −5.72 −5.73 −4.31 −4.43 −3.96 −6.48








2C19 (4GQS) X 6.0 20.7 4.6 4.1 8.8 6.0 5.2 7.7
E −3.65 −4.38 −5.44 −4.87 −5.11 −4.82 −4.37 −6.90
I GLY296 LYS270 ILE205a THR301a GLY296 LEU202a LEU366a
GLY296a
VAL113a
2D6 (2F9Q) X 7.4 17.3 12.8 20.6 10.5 6.6 7.0 19.6








2E1 (3E6I) X 6.5 28.3 4.9 17.8 30.6 29.3 27.6 18.2
E −3.51 −4.79 +4.52 −4.83 −3.81 −3.86 −4.12 −5.11
I PHE298a ARG379
LYS84






3A4 (1TQN) X 5.3 3.5 10.8 10.6 8.3 4.2 4.7 12.8
E −4.51 −5.77 −4.79 −5.27 −4.10 −4.45 −3.96 −6.10






X – distance between Fe and reaction center (Å), E – lowest energy (kcal/mol), I – Interactions
Dimensions/volume - maximal projection radius (Å), minimal projection radius (Å); van der Waals volume (Å3)
Diclofenac – 2C19 the 2nd cluster (9th ranked) is inside active site (−4.35, 4.8 Å)
Testosterone – 2C9 the 3rd cluster (77th ranked) is inside active site (−5.90, 5.9 Å)
Testosterone – 3A4 the 2nd cluster (39th ranked) is inside active site (−5.82, 9.3 Å)
Flurbiprofen – 2C9 the 3rd cluster (56th ranked) is favorably inside active site (−5.33, 4.1 Å)
Theophylin – 1A2 the 2nd cluster (31st ranked) has favorably inside the active site (5.1 Å, −4.04)












be critical either, in making or marking a molecule as
potential substrate. In silico binding of Warfarin to 2C9,
testosterone to 3A4, etc. afforded results that disagreed with
crystal structures whereas docking of Flurbiprofen to 2C9,
Bufuralol to 2D6, etc. agreed with the crystal structures.
(These findings are in agreement with our earlier works,
Parashar et al. 2014). Of the combinations tested, only
CYP2C9 and CYP3A4 (both possessing large distal pockets
of ~1500 cubic Angstroms; rendering the heme distal
pocket less consequential with respect to spatial constraints)
gave similar ranking results for both blind and heme-distal
pocket grid-based dockings for their marker substrates.
Docking of select classes of drug molecules (Sartans,
Statins & Triptans) with CYP2C9 and CYP3A4
Table 8 shows the docking of different Sartans (The
details of molecular structure and reaction schema are
given in Additional file 1A, Figure A1D.) to the
CYP2C9 pdb files 1R9O and 1GO2 respectively. It is
known that Irbesartan and Losartan are efficient sub-
strates, Candesartan and Valsartan are poor substrates
and Tasosartan and Olmesartan are not substrates of
CYP2C9 (Kamiyama et al. 2007; Berellini et al. 2005;
Perrier et al. 1994; Sica et al. 2005; Stearns et al. 1995).
Binding of Sartans (that possess a relatively large and
well presentable pharmacophore, which contributed
to ≥ 1/2 the surface area/volume of the whole drug
molecule) with 1R9O were seen to be at different loci
in blind and heme-distal site centred dockings. In blind
docking, the Sartans always bound with better energy
terms outside the heme distal pocket (Additional file
1A, Figure A1E). When considering centred binding at
the distal heme pocket, all Sartans (substrates or non-
substrates) bind in a similar fashion, with comparable
energies and orientation of reaction sites. (The image is
shown in Additional file 1A, Figure A1E) In these cases
(and also in blind docking), the heme-Fe to reaction
centre on the substrate distance is not conducive for
direct oxygen transfer. The Sartans and/or its derivative
possessing a carboxy moiety on the R-group were either
inefficient substrates or efficient inhibitors of CYP2C9
mediated metabolism. Since these molecules bind at
identical loci (interacting with the same amino acids)
within the heme pocket, the difference in substrate
reaction or inhibition potency is difficult to be
explained merely by an active site binding hypothesis.
More importantly, rather than the active site position-
ing, substrate reactivity per se and also the interfacial
ROS (reactive oxygen species) modulation by such
molecules could explain the outcomes (Parashar et al.
2014). With 1GO2, 6/8 of the blind docking and
centred docking gave similar clusters. Though binding
energies are more favorable in the heme distal pocket
centred docking, the distances are still too high to
explain for activities. Once again, distal heme-pocket
binding mechanism is inadequate to explain the re-
activity or specificity of Sartans with this structure also.
The six chosen Statins had two different small
pharmacophore groups, as shown in Additional file 1A,
Figure A1F. It is known that Fluvastatin and Pravastatin
are efficient substrates, Lovastatin is poor substrate
whereas Mevastatin, Simvastatin and Atorvastatin are
not metabolized by CYP2C9 (Neuvonen et al. 2008;
Bellosta et al. 2004; Chapman and McTaggart 2002). The
pharmacophore posed ≤ 1/2 area/volume contribution to
the whole molecule. The results of docking these mole-
cules to CYP2C9 (1R9O) are shown in Table 9 (and the
centred docking image is shown in Additional file 1A,
Figure A1G). Two drugs with the common flurophenyl
pharmacophore, Fluvastatin (substrate) and Atorvastatin
(not a substrate), bind at similar locus in heme-pocket
centered docking (though presentation of reaction centre
varies), when the most energy-minimized conformations
are taken. The second most preferred binding conformer
(w.r.t. binding energy) of Atorvastatin presents favorably
near the reaction centre, at a comparable energy term
(as required by Fluvastatin to achieve the same distance
from reaction centre). Therefore, the reactivity of these
two statins is not explained by heme-pocket substrate
bound reaction model. On the other hand, blind docking
gave very different energy values for these two Statins
(with much lesser affinity for Atorvastatin in comparison
to Fluvastatin) and they were found to bind at different
loci on the protein. The four Statins with bicyclohexenyl
pharmacophores could be graded into three classes-
Pravastatin (good substrate), Lovastatin (weak substrate)
and Mevastatin/Simvastatin (not substrates). The hydro-
phobicity of these Statins increase in the order 2 < 4 < 3
< 5. The binding energies decrease (as expected) and dis-
tance of reactive moiety from the iron centre become
more favorable for these four statins in the same corre-
sponding order. Of these, three interact with the same
amino acid(s) at the active site, although with similar
orientation of the pharmacophore and presentation of
the reaction centre. Simvastatin (the most hydrophobic
of the Statins, not a substrate), afforded the most prox-
imal orientation of the reaction centre (4.8 Å), when
compared to the value of 10.6 Å for the substrate Prava-
statin (the least hydrophobic of the statins). Mevastatin,
though more hydrophobic than Pravastatin, can ap-
proach the heme centre at 4.7 Å (for the 10th ranked
conformer, with a binding energy of ~ −7.5 kcal/mol),
but yet, it is not a substrate. Therefore, once again, “the
substrate binding the heme-distal pocket followed by re-
action” model falls short at explaining the reactivity of
the Statins. In blind docking, the four Statins were found
to bind at different loci on the protein (as shown in
image Additional file 1A, Figure A1H).
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The docking studies with Sartans and Statins show
that although blind dockings of some substrates gave
similar results when compared to heme-distal pocket
centred dockings, yet other substrates gave quite differ-
ent docking sites in the blind docking. Also, for a given
CYP, several non-substrates were found to have compar-
able binding energies (and even better relative orienta-
tions) to substrates. Further, it is difficult to visualize
how a molecule like Atorvastatin could ever get to be
oxidized by CYP3A4 at the ortho (and not para) position
on the terminal phenyl ring (Additional file 1A Figure
A1F), if the reaction were to occur at the spatially con-
strained heme centre.
Triptans, possessing a central indolyl pharmaco-
phore, were chosen as a probe for CYP3A4 and the re-
sults are shown in Table 10. (The details of molecular
structures and reaction schema are given in Additional
file 1A, Figure A1I.) Only Eletriptan, Almotriptan and
Naratriptan are known to be substrates of CYP3A4
(Evans et al. 2003; Salva et al. 2003; Sternieri et al.
2006; Moore et al. 2002; Wild et al. 1999; Vyas et al.
2000). Blind and centred docking gave different
Table 8 Sartans-CYP2C9
No. Substrate Reaction Dimension
/Vol. (Å/Å3)
CYP2C9-1R9O top row; CYP2C9-1GO2 bottom row










1 Irbesartan Hydroxylation 8.11,
6.21;
397




















3 Exp – 3179 Oxidation 8.22,
5.67;
322






















5 Candesartan O- Deethylation 8.24,
5.39;
383





−6.34 8.3 GLY98 (+)
6 Valsartan Hydroxylation 8.43,
5.94;
410
−5.65 20.7 LYS72 −7.31 8.4 ARG108 (+)
−4.79 23.7 LYS273 −6.47 7.3 GLY98
PHE100
(+)
7 Tasosartan (CYP3A4 substrate) 8.59,
5.32;
362
−8.00 nk PRO221 −9.25 nk LEU208 nk
−6.65 nk PHE100 −8.53 nk PHE100 nk














Dimensions/Volume - maximal projection radius (Å), minimal projection radius (Å); van der Waals volume (Å3); For 7 & 8, reaction site not known. - bad presentation, +
good presentation, (+) moderate presentation (not optimal but not facing the opposite end either); a - no direct interaction, neighborring amino acids provided
































































6 Rizatriptan N-Demethylationa 6.17,
5.56;
259
−3.64 16.5 CYS239 −5.62 7.9 ARG372
SER119
-
Dimensions/Volume - maximal projection radius (Å), minimal projection radius (Å); van der Waals volume (Å3). - bad presentation
aN-demethylation is assumed as the reaction centre
Table 9 Statins-CYP2C9
No. Substrate Reaction Dimension
/Vol.(Å/Å3)
CYP2C9-1R9O




















2 Pravastatin Hydroxylation, C3’- 7.65,
6.25;
415










−6.63 19.6 LYS72 −8.18 10.4 ASN204
VAL292
(+)
4 Mevastatina Hydroxylation, C3” 7.06,
5.42;
385





















−5.28 17.9 ARG108 -
Dimension /Volume- maximal projection radius (Å), minimal projection radius (Å); Van der Waals volume (Å3)
- bad presentation, + good presentation, + moderate presentation (not optimal but not facing the opposite end either)
The second preferable binding for Atorvastatin is −4.15 kcal/mol, with 3.8 A from iron center, once again binding to Arg 108. For Fluvastatin to achieve the same
distance from the reaction center, a binding energy of −5.78 kcal/mol was noted
aMetabolized by CYP3A4; underlined numericals have more structurally similar pharmacophores
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binding locations for the Triptans. In the heme distal
pocket-centred docking, a substrate is bound in the
same manner as a non-substrate. Presentation is not
favorable in the active site, with more than 7 Å dis-
tance in each. In blind docking, all Triptans bind to a
conserved but different locus within the heme-distal
pocket. Neither binding energy analysis nor substrate
proximity/orientation (within the heme distal pocket)
could afford a convincing explanation for Triptan
substrate preferences or reactivity for CYP3A4.
Demarcating substrate preferences between related and
unrelated CYPs
Table 11 shows the blind and centred docking results for
Omeprazole binding with two highly related CYPs- 2C9
and 2C19. Omeprazole is a substrate for CYP2C19, but
not of CYP2C9 (Äbelö et al. 2000). In the heme-pocket
centred docking, both 2C9 and 2C19 gave similarly
bound substrate molecules, with comparable binding en-
ergies and orientations. [The docking results (images)
are given in Additional file 1A, Figure A1J 1 & 2.] The
blind docking gave different Omeprazole binding loci on
the proteins (which showed a greater proximity of
Omeprazole to the heme centre in CYP2C19), which
could tentatively explain the preference of CYP2C19 for
the substrate.
Table 12 shows the result for the in silico binding of
various oxyresorufins with two relatively unrelated
CYPs- 1A2 & 3A4. For 1A2, alkyloxyresorufin is the
preferred substrate, with -C2H5 being the optimal
side-chain and much lower activities being observed
with larger or smaller substitutions. On the other
hand, 3A4 shows preference for an aryl substitution
and little activity with smaller/linear chain substituent
(Kenworthy et al. 1999). The heme-pocket centred
docking results indicate that enhancement of substitu-
tion bulk affords better binding energy terms without
any significant alteration of the substrate binding
locus and presenting modalities, for all substrates, in
both 1A2 & 3A4. The centred docking shows that all
four substrates are poorly presented to 1A2. In com-
parison, 3A4 is seen to bind all four substrates at the
active site in relatively favorable modes [Images of
these docking results are given in Additional file 1A,
Figure A1K 1–4]. Therefore, the heme-distal pocket
binding-based reactivity cannot adequately explain the
preference of ethoxyresorufin by 1A2 and benzyloxyr-
esorufin by 3A4. In contrast, changing the substituent
alters the binding locus and modalities in both 1A2
and 3A4 for blind dockings, thereby offering scope for
explanation of kinetic preference of substrates.
Revisiting the classical mutation experiments of RLP
Lindberg & M Negishi with the crystal structures of
CYPs- 2A6 & 3A4
Coumarin is the natural substrate for CYP2A6 and
testosterone is for CYP3A4 (Yun et al. 1991; Wang et al.
1997). It was seen in a pioneering study in 1989 that
mutating a single residue (P209L) in CYP2A6 changed it
to a testosterone hydroxylating enzyme, akin to CYP3A4
(Lindberg and Negishi 1989). Table 13 reports the dock-
ing data for probing these salient observations.
For coumarin, both docking grids gave similar results
in the two wildtype and the two mutant CYPs. That is-
coumarin bound in the same locus in these enzymes
(within the distal pocket) regardless of the modality
employed for docking or mutations made (Table 13)
[The docking results (images) are given in Additional
file 1A, Figure A1L 1–4]. Therefore, the hitherto
considered mechanism fails to explain the loss/gain of
activity when there is an extremely similar binding of
coumarin inside the heme distal pocket in the wild type
and mutated 2A6/3A4. If the presentation and binding
of substrate at the heme distal pocket were to be cru-
cial, then testosterone should be a good substrate for
CYP2A6. In CYP3A4, the high loss of activity observed
with mutation of Leu 209 (the crystal structure Leu
210) to Phe 209 cannot be explained by a heme-distal
pocket centred binding. Leu 209 is ~14 Å away from
the heme (and ~7 Å away from the distal pocket chan-
nel at the closest locus) and is more closer to the sur-
face (part of the amino acid residue can be visualized
located in a small crypt on the surface; (Additional file
1A, Figure A1L 5 and 6) than to the heme floor. It does
not form the entrance of any of the three major chan-
nels that lead to the distal cavity. Further, it is difficult
to imagine testosterone presenting itself in the heme
distal pocket in a suitable manner (to undergo oxygen
rebound at the heme centre), unless there is a large-
scale opening up of the distal site. The two mutations
(Ala 117 to Val 117 & Leu 365 to Met 365) that affect
both coumarin and testosterone activities of CYP3A4
Table 11 Omeprazole – 2C9 and 2C19
Substrate Enz. Blind docking Centred docking
Lowest Energy (kcal/mol) Distance (Å) Interactions Lowest Energy (kcal/mol) Distance (Å) Interactions Presentation
Omeprazole 2C9 (1R9O) −5.31 19.9 PRO37 −6.99 17.1 (2.5) LEU208 -
2C19 (4GQS) −4.43 12.8 ALA206 −6.51 10.5 (2.6) ASN107 -
- bad presentation
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are stuffed into the protein core, located at ~4 Å and
~10 Å respectively (at the most proximal loci with re-
spect to the distal pocket/channel). In blind docking,
testosterone binds to CYP3A4 at a crypt adjacent to
Leu 209, with a binding energy of − 4.7 kcal/mol. If
binding of the substrate to the surface was important
to catalysis, we could explain the mutation’s outcome
for CYP3A4. Significant loss of activity for coumarin
is seen in CYP2A6 only with a simultaneous alter-
ation of all three residues, Val 117, Phe 209 & Met
365. These resides are found on different loci within
the protein (different helices/loops). Met 368 (perhaps
the same as Met 365 in the earlier literature) is far
away from the channel that leads to the heme. Heme
pocket - centred docking of testosterone with the
homology models (with the mutated residues) gave
slightly different results, when compared to the wild
type. But these slight differences in binding energy
and distance also fail to explain the complete reversal
of activity of 2A6 and 3A4.
Table 13 Coumarin/Testosterone : CYP2A6 (1Z11) & CYP3A4 (1TQN)
Substrate Enz. Blind docking Centred docking
Lowest Energy
(kcal/mol)
Distance (Å) Interactions Lowest Energy
(kcal/mol)
Distance (Å) Interactions Presentation
Coumarin 2A6 −5.83 5.4 ASN297 −6.33 5.1 (2.8) ASN297 +
m2A6 −5.83 5.6 ASN297 −6.16 6.2 (4.3) ASN297 LEU296 -
3A4 −5.42 5.0 ARG212 SER119 −5.70 4.7 (3.5) ARG212 SER119 +
m3A4 −5.11 4.8 ARG212 SER119 −5.65 4.7 (3.5) SER119 +
Testosterone 2A6 −4.83 35.6 LYS32 −5.58 8.0 (3.0) PHE107 -
m2A6 −4.68 32.1 PRO231 GLN234 −7.83 8.4 (2.9) MET205 +
3A4 −6.11 12.8 GLY436 PHE435 −6.61 10.0 (4.5) ARG212 -
m3A4 −5.95 12.8 GLY436 PHE435 −6.56 11.7 (7.8) ARG105 GLU374 ARG375 -
- bad presentation, + good presentation
m2A6 (P209L) – Test – GridB - 82nd and 96th ranks bind near the mutated residue
2A6 – Test – GridB – 87th to 89th ranks bind near the amino acid under study
m2A6 (P209L) – Cou – GridB - 7.8 Å away in 1st rank
2A6 – Cou – GridB – 4.8 Å from 1st rank
m3A4 (L210P) – Cou – 90th to 98th ~ 11 Å from the mutated residue
m3A4 – Cou – 90th to 100th ~ 11 Å from the mutated residue
m3A4 (L210P) – Test – 42nd to 95th bind around 7 Å away from the mutated residue.
m3A4– Test – 50th to 99th ranks bind with ~ 9 Å away from the mutated residue
Data given in braces – nearest distance between any atom of ligand and heme center
Table 12 Oxyresorufins- 1A2 and 3A4
Enz. (pdb) Substrate Blind docking Centred docking
Lowest Energy
(kcal/mol)
Distance (Å) Interactions Lowest Energy
(kcal/mol)
Distance (Å) Interactions Presentation
1A2 (2HI4) Methoxy-resorufin −6.02 4.5 THR124 −6.86 11.3 THR124 -
Ethoxy-resorufin −5.96 11.3 THR124 −7.15 11.3 THR124 -
Pentyloxy-resorufin −5.91 11.6 THR124 −8.05 11.5 THR124 -
Benzyloxy-resorufin −4.28 34.0 PHE239b −8.20 11.5 THR124 -





















Benzyloxy-resorufin −5.45 6.7a ARG212 −7.44 4.0 SER312
LEU483
+
- bad presentation, + good presentation
a- 3.8 Å for phenyl ring; b - no H-bonds or pi-stacking interactions (neighboring amino acids provided)
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Genetic predispositions
In the first study, allelic variation of 2C9 activity on
Bosentan was studied. The alleles 2C9*13 (L90P) and
2C9*43 (R124W) had very low Bosentan clearance (<1 %
of control) whereas 2C9*55 (L361I) has very high activity
(Chen et al. 2014). It should be remembered that
Bosentan is a very large substrate and it poses little
scope for the direct presentation of its reactive moiety at
the iron centre of distal heme pocket. Homology models
of the proteins were prepared and it was seen that none
of the amino acid substitutions caused a conformational
change in the heme distal pocket region or the overall
structure of the protein. The variant 2C9*13 (with sig-
nificantly reduced intrinsic clearance values) had a more
favorable binding energy and distance in both blind and
grid centered docking (Table 14). In the case of 2C9*43,
the slight increase in the distance inside the heme distal
pocket does not explain the very low activity seen. In
2C9*55 (the allele with highest Bosentan activity), the
least favorable binding (in terms of distance and presen-
tation) inside the active site gave the highest activity.
This is yet another indication that a heme-pocket bind-
ing based reaction mechanism is inadequate to explain
the differences in activity seen in any of the alleles
studied.
In the second study (5, 6 & 7 of Table 14), the allelic
variation of CYP2C9 activity on the marker substrate
Warfarin was studied. The alleles 2C9*3 (R125H) and
2C9*16 (T299A) have very low Warfarin clearance
(DeLozier et al. 2005). The heme-pocket grid centred
docking of the wild type and the homology modelled
alleles gave almost exact bindings in all rudiments. Once
again, the hitherto perceived mechanism does not
explain these results.
Drug-drug interactions
In Table 15, Grid 1 refers to blind docking of the sub-
strate with the protein bound to the top-ranked con-
former of modulator from its blind docking. Grid 2
refers to blind docking of the substrate with the protein
bound to the nth ranked modulator, which coincides
with the substrate’s (lone presentation) binding locus.
Overall, 20 instances of drug interactions (as reported in
literature, with particular reference to the data furnished
by the groups of Houston (Kenworthy et al. 1999), Tracy
(Wang et al. 2000) and Birkett (Miners and Birkett
1998) were investigated and the pertinent results are
shown in Tables 15 and 16. The structures of the con-
cerned molecules (substrates and modulators) are shown
in Additional file 1A, Figure A1M. Nine of these led to
inhibitions, nine were instances of activations and two
cases were concentration-dependent, leading to either
inhibitions or activations. Most importantly, it could be
seen that a molecule like quinidine could activate an
isozyme like CYP3A4 (10, when Meloxicam is the
substrate), inhibit the same isozyme (6, when Nifedipine
is the substrate) and activate or inhibit the very isozyme
depending upon its concentration (8, when testosterone
is the substrate). Further, quinidine could show
concentration-dependent effects across CYPs (7 for 2C9
& 8 for 3A4). At the outset, such effects are very difficult
to be intuitively or logically accounted for by a purely
active site or allosteric binding-based phenomenon.
Also, Occam’s razor would suggest that such mechanis-
tic processes would have little significance for physio-
logical evolution, for an active site to develop such
intricate patterns of activities.
From Table 15, it can be noted that constrained dock-
ing of the modulator at the distal pocket does not pre-
vent the secondary binding of any of the substrates at
the active site (except the case 2). We see that inhibi-
tions are not explained with the heme-pocket binding
hypothesis because in certain cases (as exemplified by 1
and 2), the distance between heme-Fe and the reaction
centre decreases upon the presence of modulator.
Further, in examples like 1 & 5, binding energy for the
substrate becomes more favorable with the presence of
modulator. Regarding activations and a concentration-
















1 CYP 2C9 Wild type 100 Bosentan −2.67 27.9 LEU222 −6.40 3.1 ASN217 +
2 2C9*13 L90P 0.92 −4.75 5.1 PHE100 −6.43 3.0 ASN217 +
3 2C9*43 R124W 0.55 −2.52 29.6 LEU222 −6.37 4.0 PHE100 +
4 2C9*55 L361I 488.89 −2.95 13.4 LEU208 −6.37 11.7 THR301 -
5 CYP 2C9 Wild type 100 S - Warfarin −5.01 11.1 ASN217 −7.28 10.7 PHE100 ASN217 -
6 2C9*3 R125H 7 −4.99 12.6 PHE100 −7.19 10.8 PHE100 ASN217 -
7 2C9*16 T299A 8 −4.48 12.3 THR301 −7.18 10.8 PHE100 ASN217 -
- bad presentation, + good presentation
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Substrate Blind docking Centred Docking
Two-ligand scenario Substrate alone
Grid1 Grid2 Two-ligand scenario Substrate alone
E (kcal/
mol)
X (Å) Interactions E (kcal/
mol)
X (Å) Interactions E (kcal/
mol)
X (Å) Interactions E (kcal/
mol)





1 2C9.Fluvastatin Diclofenaca −4.94 9.5 ARG108
ASN204
NA −6.15 18.8 LYS72 −6.79 7.4 ARG108
ASN204
−6.39 17.0 ARG108













3 3A4.Itraconazole Testosterone −6.04 12.8 GLY436
PHE435





4 3A4.Ketoconazole Testosterone −6.09 12.7 GLY436
PHE435






5 2C9.Fluconazole Warfarin −5.54 24.2 TRP212 −5.56 28.8 LYS72
ILE223








NA −4.83 9.7 SER119 −4.45 11.7 SER119 −6.55 7.9 ARG212
7 2C9.Quinidine Meloxicam −6.10 14.3 LEU208 −5.92 30.1 THR364 −5.82 14.4 LEU208 −7.19 4.2 ASN204
GLY296
−6.97 15.3 LEU208
8 3A4.Quinidine Testosterone −6.09 12.8 GLY436
PHE435





9. 2C9.Dapsone Flurbiprofena −5.67 5.0 ASN204
ARG108























NA −4.45 10.2 ALA370 −9.94 10.1 ARG212 −6.95 12.7 SER119
ARG212
ARG105
12 3A4.Budesonide Dextromethorphan −4.42 18.6 ASP217 −5.14 23.4 ASP217
ASP214
ARG243
−4.42 19.0 ASP217 −5.83 10.1 ARG212 −5.19 9.2 ARG212
13. 3A4. Testosterone Dextromethorphan −4.49 18.8 ASP217 −4.71 17.8 ASP214 −4.42 19.0 ASP217 −8.03 12.5 ALA370 −5.19 9.2 ARG212












Table 15 Drug-drug Interactions (Continued)
15 3A4. Piroxicam Midazolam −4.50 14.4 PRO429 NA −4.62 12.1 ARG372 −9.32 9.2 SER119 −7.09 5.2 ARG212
16. 3A4. Piroxicam Triazolam −5.76 11.7 GLY436 NA −6.30 11.4 GLU374 −8.55 9.1 ARG212 −7.75 11.0 ARG372
17. 3A4. Budesonide BROD −4.76 23.4 PHE220
THR224





18 3A4.Clotrimazole BROD −5.24 12.9 PHE215
THR224




19. 3A4.Terfenadine BROD −4.61 17.4 VAL240 NA −5.45 6.7 ARG212 −5.92 12.8 PHE213 −7.44 4.0 SER312
LEU483
20. 3A4.Diazepam BROD −5.27 12.6 THR224 NA −5.45 6.7 ARG212 −7.46 11.4 SER119 −7.44 4.0 SER312
LEU483
X – Distance between Fe and reaction center (Å), E – lowest energy (kcal/mol)
Grid 1: Firstly, the top-ranked conformer of modulator from blind docking is taken and then, the substrate is also blind docked
Grid 2: The nth rank of blind docking of modulator, which coincides with the substrate’s preferred (lone presentation) binding locus, is taken as the rigid docking template and then the substrate is blind docked next
2C9.Flurbiprofen - the 3rd cluster (56th ranked) is similarly presented inside active site with energy of −5.33 (4.1 Å) as in 2° docking with Dapsone
Key: Underlined S. No. indicates inhibition, punctuated S.No. indicates activation and bold S. No. indicates concentration dependent effects












dependent effect, the active site based reaction mechan-
ism does not provide any consistent explanation either.
The most celebrated example of 9 shows clearly that the
substrate’s reaction centre goes much farther than the
instance lacking the modulator. It is difficult to think
that activation could also arise because of multiple mole-
cules’ simultaneous presence in the active site. Further, it
is difficult to imagine how the presence of a modulator
could affect minute changes in docking modalities,
which could in turn enhance rates by ~400 % in 10 & 11
(Kenworthy et al. 1999). In 7 & 8, contrasting results are
seen for the same experimental effect of concentration
dependent activation/inhibition. That is- in 7, the pres-
ence of modulator makes binding energy more negative
and Fe-substrate reactive moiety distance decreases;
whereas in 8, the presence of the very same modulator
makes the binding energy more positive and the Fe-
substrate reactive moiety distance increases. In at least
four cases (1, 9, 10 & 11), the substrate could still inter-
act with the same key amino acid residues within the ac-
tives (in spite of major or minor change in presentation
modes).
Blind dockings of various substrates/modulators show
diverse binding loci on CYPs’ surface or regions adjacent
to proximal/distal cavities. The distance of the reaction
centres are diverse and so are the binding energy terms.
In certain instances, binding loci are conserved across
substrates (Diclofenac and Flurbiprofen bind at Lys 72)
and modulators (Dapsone and quinidine bind at Trp
212), as exemplified by 1 & 9 for CYP2C9. This type of
paradigm was also seen for many molecules from
Statins, Sartans and NSAIDs classes for CYP2C9.
(The respective images are shown in Additional file
1A, Figure A1N 1.) In blind docking of individual
molecules (Table 15- as seen from 1, 6, 9 & 11- com-
binations of different CYPs, substrates and modula-
tors), the substrate or modulator molecules bind to
the same respective loci within CYP3A4. (Additional
file 1A, Figure A1N 2) Even in blind docking with re-
spect to Grid 1, while instances like 6 & 9 (inhibition
and activation respectively) could be explained by “ac-
tive site” considerations, cases like 1 & 11 (inhibition
and activation respectively) speak against the erstwhile
assumptions. This is further consolidated by the Grid
1 data in cases 2, 3, 4, 5, (for inhibitions) 7 & 8 (for
concentration dependent inhibitions/activations) and
10 (for activations), where the substrate binding does
not get perturbed significantly by the presence of
modulator. Even more, Grid 2 blind dockings, it can
be seen that in 2, 3 & 4 (for inhibition), 10 (for
activation) and 7 & 8 (for concentration dependent
activation/inhibition), the outcome cannot be ex-
plained by a heme-pocket binding-based phenomena
alone. (The binding energy changes remain similar
and the Fe-substrate reaction centre distances are
unfavorable.)
Budesonide and testosterone have very similar struc-
ture but show varying effects on dextromethorphan
metabolism. Budesonide acts as an inhibitor whereas
testosterone acts as an activator. From the entries in 12
and 13 of Table 15, it can be seen that the presence of
both modulators had very similar effects on dextrome-
thorphan binding across all grids, thus failing to explain
the activation and inhibition seen. In another case, the
same modulator has varying effects on substrates having
similar structures (15 and16). Piroxicam inhibits Mid-
azolam whereas it activates Triazolam metabolism. This
is when the docking shows that presence of Piroxicam
shifts both of the substrates to the same locus (with
similar binding energy). Once again, the erstwhile para-
digm does not explain the differences in the activity
seen.
In the cases of modulators studied 17 through 20, it is
known that Clotrimazole fully inhibits BROD metabol-
ism whereas Budesonide, Terfenadine and Diazepam ac-
tivate the same by several folds (Kenworthy et al. 1999).
In active site docking, the presence of activators pushes
the reaction site in the substrate from 4 Å to ~8–13 Å
respectively (in some cases, even farther than what the
“fully inhibiting Clotrimazole” does), making it non-
viable for a more effective direct oxygen rebound. The
activation of Dextromethorphan metabolism brought
about by Diazepam (14) also follows the paradigm seen
above.
Most modulators studied had either a heterocyclic or
free amine nitrogen atom, possessing a lone pair.
Thereby, they could be potentially capable of affecting
the heme centre by a direct Type II interaction. Table 16
shows that all modulators’ (or substrates’) forced binding
at the distal heme pocket of the concerned CYPs gave
Fe-interactive (reactive) moiety distance ranging from 4
to 20 Å, non-conducive for a direct ligation or oxygen
rebound. The distal pocket site docking results shown
for the modulators (Table 16) indicate that none of the
molecules (except perhaps 9, 10 and 16) present them-
selves in a favorable way, towards this outcome. While
the active sites of the concerned CYPs offer space to ac-
commodate a majority of the modulators, some large
molecules (like 2) are docked with a significant part
interacting freely with bulk solvent. Further, the orienta-
tions of the molecules were many times inappropriate
for a preferred modality of substrate activation/inter-
action. The entries 13 through 16 are not discussed in
Table 15 but they are important with respect to Houston
group’s data with CYP3A4 (Kenworthy et al. 1999).
[Gentamycin did not significantly inhibit or activate any
of the 10 substrates of CYP3A4 (or CYP1A2 catalyzed
metabolism of EROD). Nimodipine and Nitrendipine
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(like Nifedipine) inhibited all substrates (lowering
CYP1A2 activity for EROD marginally). Roxithromycin
inhibited some and did not perturb others (leaving
CYP1A2 activity unperturbed).] The binding of these
molecules at the distal site of CYP3A4 did not afford
any insight upon the experimental effects observed. An-
other important aspect to note was that azoles like
Clotrimazole, Itraconazole and Ketoconazole lowered
CYP3A4 activities for all substrates, when all of these
‘azole’ modulators did not possess effective coordination
abilities (via the heterocyclic nitrogen) with the heme-
iron centre (as seen in entries 1 through 3 of Table 16).
Only Clotrimazole inhibited EROD activity of 1A2 and
we explored blind docking to see if the ‘azoles’ bound
differently with the two CYPs. Blind docking of Clotri-
mazole to CYP3A4 was at a locus quite adjacent to the
CYP’s proximal thiolate and only Itraconazole showed
favorable binding in the distal heme pocket (Additional
file 1A, Figure A1O). In CYP1A2, the ‘azoles’ docked at
a superficial crypt. It is highly unlikely that Clotrimazole
or the other large azoles (Ketoconazole & Itraconazole)
gains access to the heme distal pocket at low















1 Clotrimazole 3A4 5.91, 5.66;
311
−3.83 10.1 GLY436a −5.30 10.2 ARG212a -
1A2 −3.14 36.3 LEU51a nd nd nd
2 Itraconazole 3A4 11.32, 6.73;
529
−5.31 27.6 PRO227 −4.18 21.1 Val240 LYS173
TYR307 SER311
-
1A2 −3.50 33.7 ILE241 nd nd nd
3 Ketoconazole 3A4 11.55, 5.40;
453
−3.78 29.1 VAL240a −6.64 10.5 ARG212 -
1A2 −3.69 37.5 VAL54 nd nd nd
4 Hydroquinidine 3A4 6.72, 5.86;
320
−5.35 4.8 ARG212 −6.70 9.8 ARG212 (+)




−6.56 9.2 ALA305 ARG212 -
6 2C9 −5.33 18.4 TRP212 −7.01 9.0 LEU208 -
7 Fluvastatin 2C9 6.94, 6.24;
383
−5.05 19.6 PRO221 LYS72 −6.80 7.4 ARG108 ASN204 (+)
8 Fluconazole 2C9 5.35, 5.72;
247
−3.88 4.0 ARG108a −4.65 7.6 GLY296 ARG108 -
9 Dapsone 2C9 6.30, 4.41;
211
−4.36 20.9 TRP212 −5.11 3.2 THR301a
ALA297a
+
10 Diazepam 3A4 6.10, 5.29;
246
−5.64 9.3 ARG105 GLU374 −6.50 5.0 ARG212 +
11 Terfenadine 3A4 8.61, 5.79;
487
−4.98 17.7 ARG372 −8.33 10.6 ARG212 -
12 Budesonide 3A4 7.77¸ 5.98;
406
−5.10 7.7 ARG212 SER119
ALA370
−6.89 7.7 ARG212 SER119
ARG372 GLU374
(+)
13 Gentamicin 3A4 8.36, 5.99;
476
−1.86 16.8 VAL240 CYS239 −4.77 10.8 ARG212 ARG372 -
14 Roxithromycin 3A4 9.16, 7.03;
829
−0.46 24.8 LYS209 ARG243
ASP217
+2.67 6.9 PHE213 ARG212
GLU374
(+)
15 Nimodipine 3A4 7.48, 5.80;
376
−3.79 25.1 VAL240 CYS239
ARG243
−8.45 10.0 ARG212 ARG375
GLU374
-
16 Nitrendipine 3A4 6.90, 5.65;
318
−4.89 13.7 ARG212 ARG106 −7.51 5.8 ARG212 ARG375
GLU374
+
17 Piroxicam 3A4 8.02¸ 4.83;
269
−4.78 10.0 ARG106 −6.71 12.2 ARG212 ARG372 -
Dimension /Volume - maximal projection radius (Å), minimal projection radius (Å); Van der Waals volume (Å3)
- bad presentation, + good presentation, (+) moderate presentation (not optimal but not facing the opposite end either)
aNo H-bonds or pi-stacking interactions (neighboring amino acids provided)
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concentrations of the enzyme. While the in silico bind-
ing of CYP3A4 shows that Ketoconazole binds effect-
ively at the surface of CYP3A4, the crystal structure
showed two molecules docked within the heme distal
pocket (Ekroos and Sjögren 2006). When compared to
the drug metabolism data, the crystal structures do not
make much sense because Ketoconazole’s primary
metabolizer is CYP3A4 (Fitch et al. 2009). Clotrimazole,
a facile one-electron redox active molecule, could even
alter the redox status within the microenvironment by
directly interacting with superoxide/radicals in free
solution.
Docking of methylstyrenes (for reactions involving
oxygen insertion across an activated benzylic double
bond) with hemeproteins and the issue of
enantioselectivity
It is known that the crystal structure allows the explan-
ation of stereoselective reactions in chloroperoxidase, a
fungal soluble P450 (Sundaramoorthy et al. 1998). Dy-
namic movements of certain residues have also been re-
ported to be responsible for the enantiotopic recognition
near the heme centre (Morozov et al. 2011). The con-
formation of the heme distal pocket is known to critic-
ally affect the enantioslectivity involved in CPO. The
results of docking of cis-betamethylstyrene with CPO/
P450cam (Table 17) were compared with para-methyl-
styrene’s aziridination using mutants of P450BM3. In
CPO, the presentation of the substrate is close to the
heme-iron. Experimentally, this reaction gave high en-
antiomeric excess (ee) with high product yield (and this
was in spite of the relatively harsh reaction system with
low pH and high peroxide concentration). In P450cam
(with a relatively mild reaction condition at neutral pH
and reductant), the access to heme centre is not as
closer (but binding energy was marginally better) and as
a result, relatively lower ee was observed. (There was no
information provided on the yield of the product or
side-products formed in the reaction. Since P450cam
gives side-products even with camphor and its analogs,
cis-betamethylstyrene should be no different.) This may
be an indication that the oxygen transfer is not strictly
mediated at the heme centre in P450cam. The recent
publication from Arnold group (Farwell et al. 2015)
reported the bulky tosyl azide moiety insertion across
the styrene’s double bond in an aziridination reaction.
This reaction is similar to the oxygen insertion across
styrene’s double bond (which gives epoxide). It is seen
that the efficient mutant (that affords higher ee and
product yield) allows proximity of the double bond to
the heme centre and also gave better yields. Therefore,
docking with the plastic crystal structure does give some
qualitative idea about interactions of substrate at the
heme floor in CPO, P450cam and P411BM3 (modified
P450BM3).
Can detachment of products from the distal heme pocket
(‘active site’) serve as the end of catalytic cycle (as sought
by the existent hypothesis)?
Table 18 compares the centred and blind docking data
for some CYPs with their substrates and primary prod-
ucts. The binding energy terms of the substrates are
comparable to the products, and at times (as is seen in
case 1), the products have better binding energy terms
than the original substrate. The interaction of substrate
and product is very similar for a given enzyme-substrate
combination. Some products of a given CYP have more
favorable binding energy than another substrate of the
same CYP. These simple findings question the assump-
tion that hydroxylations prompt the substrate to leave
the active site, owing to a lowering of affinity. Quite sim-
ply, there is little chemical logic for the “committed sub-
strate” to leave.
Meta-analysis of kinetic and equilibrium constants,
residence and reaction times
We analyzed the kinetics data retrieved from literature
for two prominent liver microsomal CYPs. As shown in
the Table 19, the KM (and Ki) for diverse substrate(s) of
CYPs 2C9 and 2E1 (determined by different workers, in
various reaction systems) ranges between a few micro-
molar to several hundred or thousand micromolar
ranges, which is an “unacceptable” spread in the value of
constants.
Table 17 Heme-distal pocket centred docking of methyl styrenes with some non-microsomal hemeproteins (CYPs)
No. Substratea Enzyme Lowest
Energy
Distance Interactions Presentation EE of
prdt.
Yield Rate Ref.
1 CBMS CPO −4.69 3.5 GLU183b PHE103b + 96 % 92 % na (~10/ min) (Allain et al. 1993)
2 CBMS P450cam −5.60 6.9 TYR96
b THR101b - 78 % na ~1/min (Ortiz de Montellano
et al. 1991)
3 PMS P411BM3-CIS-T438S$ nd nd nd 25 % 1.1 % na (Farwell et al. 2015)
4 PMS P411BM3-CIS-T438S (I263F) −4.42 3.0 ALA264 55 % 40 % na (Farwell et al. 2015)
aCBMS cis-betamethylstyrene, PMS para-methylstyrene, Energy and Distance given in kcal/mol & Angstroms respectively. bNo hydrogen bonds or pi-stacking but
neighboring amino acids provided. Docking of 4 with tosyl azide gave docked molecules within 2.7 A of the heme iron, with ~ −4.15 kcal/mol energy term and it
interacted preferably with ALA330. Docking was not done with 3 owing to unavailability of protein structure
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Further, we analyzed the value of Kd (as determined by
in silico binding and in vitro protein-solution binding)
and compared it with experimental KM (Table 20). We
see little correlation between experimental Kd and ex-
perimental KM. (At times, a theoretical breach occurs
when some experimental Kd values are larger than ex-
perimental KM values, as seen in 3, 9, 10 & 12. Also, it is
difficult to imagine a several folds higher experimental
KM in comparison to Kd, as is seen in 2, 5, 8, 11.) Except
for 9 & 12, there is little correlation between experimen-
tal Kd or experimental KM with in silico Kd (distal pocket
docked). But, even in 9 & 12, we have a theoretical fal-
lacy that experimental KM is smaller than experimental
Kd. This cannot be disregarded merely as an inefficiency
of docking programs. In the blind dockings, the in silico
Kd values are higher than the experimental Kd. (Pre-
dicted solubility or log P values are not highly different
from experimental findings.) There exists no correlation
between residence time (as calculated from in silico Kd
or experimental Kd or experimental KM) with experi-
mental conversion time. The magnitude of conversion
time is higher than the residence times by 103 (lowest
limits as seen in 8 and 9) to 108 (higher limits as seen in
3 and 12). These differences are not trivial or small and
therefore, the “committed to catalysis” hypothesis must
be rendered invalid. If we have to buy that proposal, we
should also accept that the most inefficient or poor
substrates have the highest binding efficiency to a given
CYP! This cannot be supported with any in silico or ex-
perimental data anyway. (Further, it counteracts the
very purpose for which the hypothesis was invented.)
The overall conversion time is low (<10 seconds) for
“smaller and leaner” molecules with relatively unob-
structed reaction site and it is not low for tight binders
(lower Kd, whether in silico or experimental) or more
reactive molecules/centres. This could show diffusion
constraints in reaction kinetics.
Discussion
Establishing the need for this work
In the current work, we investigate the application of the
“plastic crystal structure” (as available from pdb files de-
posited by other researchers) to afford insight into the
purported “elastic dynamics” of CYP-substrate interactive
mechanism. At the outset, we must state that exploring
the dynamic interactions of a squishy “breathing” protein
located in a semi-mobile phospholipid environment with
a static protocol like molecular docking is not necessarily
a very apt method. But then, one simple question contin-
ued to bother us- if the F and G loops move to accommo-
date all substrates of a given CYP within the heme distal
site, why is it that only some substrates are reacted by the
‘high potential Compound I’ of a given CYP? Further, our
zeal to undertake the current study was fueled by the curi-
osity generated upon noting the inadequacy of the erst-
while hypothesis. It is known that reaction dynamics of
several CYPs do not show a classical Michaelis-Menten
paradigm for initial kinetics under steady-state conditions
(Atkins 2005). Furthermore, several aspects (as noted
from literature) speak out against a mere heme-centred
active-site hypothesis:
Table 18 Comparing the docking of substrates and products
Enzyme
(PDB ID)
Ligand Blind docking Centred docking
Lowest Energy
(kcal/mol)
Distance (Å) Interactions Lowest Energy
(kcal/mol)
Distance (Å) Interactions Presentation





−5.37 6.7 PHE304 −7.91 11.8 PHE304
GLU306
-












2C9 (1R9O) Diclofenac −6.15 18.8 LYS72 −6.39 17.0 ARG108 -
4’Hydroxy
diclofenac
−5.37 20.2 LYS72 −5.28 9.1 ARG108 +
2E1 (3E6I) Chlorzoxazone −4.12 27.6 LYS486
LEU463










- bad presentation, + good presentation, (+) moderate presentation (not optimal but not facing the opposite end either)
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1. Quite interestingly, upon changing the reductant or
by the introduction of Cyt. b5 / lipids (as per the
erstwhile understanding, these components should
have little influential scope to govern the substrate-
CYP interactions), the KM value changes signifi-
cantly (Parashar et al. 2014). This was when KM was
calculated using non-linear regression with only the
lower values of the substrates (that fit the Michaelis-
Menten paradigm), giving a curve that apparently
resembled a decent hyperbolic asymptote. Also, it is
common knowledge to many CYP researchers that
the overall stoichiometric yield varies with time and
also by altering the components’ initial concentra-
tions. Such observations cannot be explained if the
kinetics is critically dependent on a tight enzyme-
substrate complex formation (as the erstwhile
hypothesis solicits).
2. Kinetic Isotope Effects (or KIEs) afford us key
insight into the dynamics of substrate and enzyme
(reactive) intermediate’s interactions. The presence
of high intra-molecular KIEs (Miwa et al. 1980) in
CYP-catalyzed reactions imply that there is little
Table 19 Kinetic constants for CYPs, as noted from literature
CYP2C9
Substrate
KM Ki Ref. CYP2E1
Substrate
KM Ki Ref.
Diclofenac 5.1 ± 0.9 μM
(Baculosomes)
(Kumar et al. 2006) 4-Nitrophenol 120–140 μM (Hanioka et al. 2003)
2.6 ± 0.3 μM
(Supersomes)
1.6 μM 21 μM 42 ± 19 μM (Tassaneeyakul et al.
1993)
16 ± 2 μM,
30 ± 3 μM
(Reconstituted)
9.3 μM 108 ± 18 μM (Baranová et al. 2005)
4.0 μM (HLM) 2.9 μM (Walsky and Obach 2004;
Kumar et al. 2006)
28 μM (Chen et al. 1996)




1.84 ± 0.09 mM (Fairhead et al. 2005)
9 μM (Bort et al. 1999) 156 μM (Van Vleet et al. 2001)
3.44 ± 0.45 μM (Konečný et al. 2007) 86 μM (Patten and Koch 1995)
(S)-Flurbiprofen 16.2 ± 0.9 μM
(Baculosomes)
(Kumar et al. 2006) Chlorzoxazone 250-300 μM (Hanioka et al. 2003)
21.6 ± 0.8 μM
(Supersomes)
69 μM 47 ± 10 μM (Tassaneeyakul et al.
1993)
120 ± 10 μM,
45 ± 2 μM
(Reconstituted)
193 ± 28 μM (Baranová et al. 2005)
1.9 μM (HLM) (Walsky and
Obach 2004)
33 μM (Chen et al. 1996)
~33 μM (Hutzler et al. 2003) 0.65 ± 0.08 mM (Fairhead et al. 2005)
1.9 ± 0.4 μM 4.7 μM (Tracy et al. 1995) 50 μM (Beckmann‐Knopp et al.
2000)
~7 μM (Youdim and
Dodia 2010)
150 μM (Howard et al. 2001)
19.4 μM (Tracy 2006) 660 ± 18 μM (Shimada et al. 1999)
(S)-Warfarin 4.6 ± 0.3 μM
(Baculosomes)
(Kumar et al. 2006) Nitrosodimethylamine 212 μM (Patten and Koch 1995)
13 ± 2 μM
(Supersomes)
36 μM
32 ± 2 μM,
52 ± 9 μM
(Reconstituted)
66 μM (Patten et al. 1992)
3.7 μM (HLM) (Hemeryck et al. 1999) 59 μM
4.1 ± 0.6 μM (Rettie et al. 1992) 21.7 ± 1.5 μM
4.1 ± 0.9 μM (Lang and Böcker 1995) 22.3 ± 0.6 μM
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Table 20 Comparison of in silico and in vitro reaction / binding parameters
S.No. CYP Substrate Physical features
(in silico)
























1 3A4 Testosterone 115 μM,
3.37 & 3.3
−6.61 −6.10 14 33 72 31 81 μM, 3.32 36 (Farooq and Roberts
2010)
100 (Yuan et al. 2002) 28 10 53 (Wang et al. 1997)
2 Erythromycin 625 μM,
2.60 & 1.55




78 (Wang et al. 1997) 8 13 545 (Wang et al. 1997)
3 Amitriptyline 16 μM,
4.81 & 2.8
−4.75 ND 348 ND 3 ND 35 μM, 4.92 178 (McLure et al. 2000) 67 (Eugster et al.
1993)
5.6 15 1091 (Venkatakrishnan
et al. 2000)
4 2E1 Chlorzoxazone 17457 μM,
1.94 & 1.9
−5.49 −4.12 92 935 11 1.1 5898 μM, 1.6 ND 40 (Yuan et al. 2002) ND 25 300 (Lee et al. 2006)
5 p-Nitrophenol 25879 μM,
1.61 & 1.28
−4.86 −5.67 267 68 3.7 15 83387 μM,
1.91




44 5.1 375 (Duescher and
Elfarra 1993)
6 2D6 Bufuralol 136 μM, 2.99
& 0.81
−6.13 −4.28 31 713 32 1.4 ND, 3.5 6.2 (Guengerich 2005) 10 (Yuan et al. 2002) 161 100 5.9 (Marcucci et al.
2002)
7 2C19 Omeprazole 1039 μM,
2.43 & 2.43




1.7 (R) 6.9 (S) (Foti and
Wahlstrom 2008)
8 2C9 Flurbiprofen 102 μM,
3.94 & 1.38
−6.64 −5.73 13 61 76 16 33 μM, 4.16 0.13 (Hummel et al.
2008)
29 (Hutzler et al. 2001) 7692 35 4.8 (Hutzler et al. 2001)
9 Diclofenac 15 μM,
4.26 & 1.58
−6.39 −6.15 20 30 50 33 8 μM, 4.51 16 (Wester et al. 2003) 6 (Lewis et al. 1998) 63 167 0.7 (Liu et al. 2012)
10 Warfarin 153 μM,
2.74 & 1.34
−6.34 −5.72 22 62 46 16 55 μM, 2.7 8.2 (Takahashi et al.
1999)
5 (Yuan et al. 2002) 121 200 194 (Liu et al. 2012)
11 2A6 Coumarin 453 μM,
1.78 & 1.82
−6.33 −5.83 22 52 45 19 876 μM, 2.07 0.3 (Yano et al. 2005) 2.1 (Lewis and
Dickins 2002)
3704 476 2000 (Li et al. 1997)
12 1A2 Ethoxyresorufin ND, 2.28
& 2.42
−7.15 −5.96 5.5 42 181 24 ND, ND 5.3 (Lin et al. 2001) 1.7 (Lewis and
Dickins 2002)
189 588 2609 (Eugster et al.
1993)
The in silico ΔG and Kd values are from our studies (except 3); Kd exp is from equilibrium dialysis or Soret differential spectral analysis- found in literature
KM is any selected value reported for the enzyme-substrate combination in literature and conversion time is the time taken for one molecule of enzyme to convert one molecule of substrate to the specific product












spatial constraints and the substrate is very free to
approach the enzyme-generated catalytic intermedi-
ate. This finding means that the substrate is not
tightly bound in a preferred orientation within the
active site and is free to tumble around. (This intri-
guing result is particularly relevant for non-activated
hydrocarbons, which are the classical reactions of
high potential reactive intermediate of CYPs.) To ac-
count for this contradictory finding, some apologists
of the erstwhile hypothesis have invoked upon a
“committed to catalysis” idea (Lu 1998), which seeks
that while the CYP is bound to the substrate to ef-
fect a change in redox potential, the substrate is yet
free to rotate within the “active site”. The proposal
flouts Occam’s razor because then, each CYP needs
to have some kind of sensor(s) and processing intel-
lect to effect this proposition. So, the erstwhile hy-
pothesis does seek a case of mutually exclusive
options (obligatorily bound and freely rotating sub-
strate) at the same instant. [Let us remember that
existence of intra- or inter- molecular KIEs in CYP
reactions are not an indication that the reactions
must occur within the heme distal pocket either.]
3. At times, the experimental Ki and Kd values of an
inhibitor (Type I or Type II) for CYPs have been
reported to be lower than the enzyme
concentrations taken for assay (Locuson et al. 2004;
Locuson et al. 2003; Collom et al. 2008). To a
biochemist, inhibition of a biological process affords
the most fundamental mechanistic and
phenomenological insight regarding the crucial steps
involved and therefore, this is a critical point that
speaks against the erstwhile hypothesis.
4. Survey of substrate “preferences” of most
mammalian P450s (for the hydroxylation reaction)
do not give any clear cut ideas of active site
topologies of a particular isoform. When a CYP can
kinetically differentiate between an R and S
enantiomer of a substrate (Rettie et al. 1992), it is
highly unusual that most of the human liver
microsomal hydroxylations are not enantioselective
(i.e., do not give products with high enantiomeric
excess). Also, in exceptional cases where
enantioselective hydroxylations are observed, the
reactions are not regioselective (Dayer et al. 1982).
Hydroxylations of molecules at unactivated carbon
atoms (in either aromatic or aliphatic substrates)
seldom show any enantioselectivity. This is when
oxygen insertion reactions by the same P450s for
similar or much smaller substrates but with
activated carbon or hetero atoms with relatively
higher electron density at the reactive moiety
(olefins giving epoxides, N- or S- atom containing
substrates giving the oxides, substrates with a
sterically unhindered benzylic carbon giving
hydroxylated products etc.) showed varying levels of
enantioselectivity, depending on the substrates.
These observations do not quite go well with a
“space filling - topography - reactive moiety”
considerations for an active site process.
5. In most cases, the hydroxylation is always higher on
the energetically favorable atom on the substrate
(making CYP metabolic reactions highly predictable,
(Jones et al. 2002; Korzekwa et al. 1990), and not the
sterically favorable one. (There are exceptions to this
trend. Yet, we deem this overwhelming pattern as a
“clear tell” for the microsomal P450s’ reaction
mechanism.)
6. Jones group’s work demonstrated that it is a
diffusible radical species (t-butoxy) that best
approximates CYP catalytic process in terms of KIEs
(kinetic isotope effect) and LFEs (linear free energy
relationships) when compared to a heme-centred
Fe-pyr system (Manchester et al. 1997). This is a key
mechanistic insight that cannot be ignored.
When considering the mechanistic scheme of CYPs,
we deem spatio-temporal aspects to hold more critical
importance. And when one solves a puzzle that liver
microsomal CYPs are, the larger pieces have to be
pieced in first. We considered a possibility that some of
the observations (open-closed conformers, substrates-
bound crystals and Type II spectra etc.) could be coinci-
dental aspects, which may be inconsequential in the big-
ger picture. If we take the erstwhile “high affinity
binding at heme pocket hypothesis” to be binding, then
the endeavor of determining crystal structures would be
relegated to lesser significance because dynamic aspects
alone would determine reactivity. Under the purview of
the erstwhile hypothesis, crystal structures of diverse
CYPs do not show a discernible structure-function cor-
relation. All CYPs’ structures must be “tinkered” by
modeling/simulation to explain their reactivities, with-
out really explaining their substrate preferences. In the
light of the arguments above, considering our recent
findings (as cited in the last part of the introduction)
and the results presented in this study, we could in-
dulge in an idea that the trigger of a molecule binding
to the heme pocket need not be the sole sponsors that
afford selectivity/specificity in CYP mediated redox re-
actions. With this supposition, we justify the evolution-
ary mandate of CYPs and the inherent crystal structure
of a protein also gets its due significance. We also think
that it is quite probable that a hydrophobic protein
could be crystallized out in a number of ways, under
varying conditions, in the presence or absence of some
organic molecules. Whether these structures have func-
tional relevance is to be decided by experimental/
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functional verification. Literature also shows that in
most cases, a given microsomal CYP’s substrate is un-
able to induce the production of the same CYP (some
substrates of CYP3A4 are notable exceptions). This
showed that there was no biological/evolutionary link
for a given drug molecule’s topology to the expression
of the CYP that metabolized the same drug molecule.
[Further, it is opportune to add a disclaimer that the
example of P450BM3, a reductase-P450 hybrid, which
gives very high rates and enantioselective hydroxyl-
ations (Farwell et al. 2015), may not be very appropriate
for the liver microsomal CYP systems. In these systems,
the distal pocket’s and the access channel’s amino
acids’ role in substrate positioning/reactivity has been
well-explored and documented (Ravichandran et al.
1993; Li and Poulos 1997). Here, the reduction of
heme could be an intramolecular process, with facile
electron tunneling and proton relay. In microsomal
CYPs, the electron transfer is currently believed to be
inter-protein, and that, over apparent distances of >15
Angstroms. This seems a rather unlikely proposal].
Therefore, we had several reasons to believe that our
findings on the phenomenology involved in peroxidase
system were very relevant herein, within microsomal
CYPs. Therefore, the prima-facie case for thinking
beyond the currently available paradigm is established.
Critical dissection of the erstwhile hypothesis
The prevailing explanation for CYP catalysis (which
seeks the localizing of the substrate at the distal heme
pocket) solicits that-
(i.)the protein be highly flexible (high level of induced
fit) and this flexibility can be exercised in several
modalities (given the diverse topographies of its
substrates), and
(ii.)each substrate should have a specific locus (or
multiple loci) to bind on the protein surface or
crypts therein. Further, this substrate-enzyme
‘binding event’ should serve as a molecular trigger
for four obligatory outcomes -
(a)alteration of redox potential of the heme centre,
(b)“commitment of substrate to catalysis”- that is, the
substrate should not dissociate through the
subsequent steps of the catalytic cycle and must
remain ‘bound and localized’ within the distal
pocket,
(c)presentation of the substrate within suitable bonding
distance at the heme centre, for oxygen rebound &
(d)a proton shuttle must deliver protons at the heme
distal site for substrate hydroxylation.
This must be orchestrated in a precise sequence of
events, as follows- 1. First, substrate should bind to the
distal site of CYP and it should be concomitantly
followed by CPR binding at the protein’s periphery.
Then, a molecule of oxygen should diffuse into the distal
pocket of the erstwhile complex, thereby giving yet an-
other ternary or quaternary complex. All these fastidious
requirements mock Occam’s razor and simple notions of
probability. It is difficult to imagine how a single protein
could/should evolve the “molecular intelligence” for the
metabolism of diverse xenobiotics through a highly com-
plex process, sans chemical or biological logic. From
data given in this work (particularly, Tables 2, 3, and 4),
one would challenge the very premise of the requisites
sought by the erstwhile paradigm. This is because the
crystal structure shows that a CYP like 2E1 does not
have any channels leading into the distal pocket. Other
CYPs have some channels but most of them have too
small dimensions (the substrate molecular dimension is
at least twice the constrictions of the channels within
the protein) afford any probability for a direct diffusion
of the substrate molecule to “the locus of catalysis” (the
distal heme centre). Further, some substrates are too
large to be even accommodated at the active site itself,
even if it were to open up in a reasonable way.
But apologists of the erstwhile hypothesis could argue
that the classical model of P450Cam also shows no cavity,
and yet, it is very well known that camphor does show a
Type I binding in the distal heme pocket. Therefore, if the
soluble protein of P450cam is “flexible” enough to allow
movement of camphor into the distal pocket, the mem-
brane proteins like microsomal CYPs can also be envis-
aged to be flexible. Though membrane proteins are seen
as ‘squishy’ proteins, they are also known to bind ligands
with high specificity, thereby indicating a high level of sur-
face plasticity. Very importantly, the hydrophobic
phospholipid microenvironment can be imagined to be a
constrained and low-energy microcosm, which is only
semi-fluidic. The distal pocket may be large in many CYPs
but access to it is definitely constrained. To imagine that
small amounts of diverse substrates could repeatedly find
the probability to - (i) bind outside and get transported to
the inside or (ii) squeeze their way in or (iii) the enzyme
would welcome the molecules by opening and closing up
through some undefined logic - is seeking repeated
sequence of events of low probability (with respect to mo-
lecular dynamics). Even if some of these large molecules
gathered access to the heme floor, we envisage that it is
disadvantageous for a direct oxygen transfer to any hin-
dered locus within framework of a rigid substrate, within
the constrained heme distal pocket. We speculated that it
may not be mere coincidence that microsomal CYPs’ sub-
strate selectivity or docking orientations do not correlate
with reactivity or yield.
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For the enzyme catalyzed reaction (where E is enzyme,
S is substrate and P is the product)-
E þ S↔ ES −− EP→ E þ P
let us assume that k1 and k−1 are the forward reaction
rate constant to form ES complex and the backward
breakdown rate constant of ES, respectively; and k2 is
the forward breakdown rate constant of EP complex.
Then,
k1 ¼ d ES½  = dtð Þ : 1= E½  S½ ð Þ
Theoretically, for nM levels of CYPs and μM levels of
substrate (the usual working ranges for in vitro studies),
we can have only < nM ranges of [ES] formed in >milli-
seconds (which is the generally accepted “breathing
time” of proteins, the time that would be required for F/
G loops/helices to move around). So, the k1 for this re-
action alone can be lower than 107 M−1 s−1 or be up to
the theoretical maximum of 109 M−1 s−1. Experimentally,
nM levels of CYPs give product formation with pseudo
first order rates equalling 1 per second (for efficiently
coupled baculosome systems in vitro). For such systems,
the overall reaction cycle’s second order rate constant
achieves diffusion limitations for this single step alone.
So, the diffusional constraints and probabilistic barri-
cades involved in an ordered (sequential) reaction of
multimolecular collisions/complexations of at least five
components (nM levels of CYP & CPR and micromolar
levels of oxygen, substrate & NADPH) are unaccounted
for. Quite simply, under the purview of the erstwhile hy-
pothesis, collision/complexation frequencies of bulky
hydrophobic proteins and drug molecules cannot
achieve such super-concerted orchestration of events
(that exceed diffusion limitations) at the phospholipid
interface. This ‘kinetic’ argument is the most compelling
quantitative logic against the erstwhile hypothesis.
A new hypothesis, its stimulus and crux
Recently, we have argued that the efficient Type II bind-
ing of a ligand at the heme distal pocket is seen only at
high concentrations of the enzyme (into micromolar
ranges) and at very high ligand pressures (Parashar et al.
2014). The same logic would be held viable for Type I
bindings too. In physiological conditions, it is highly un-
likely that such high concentrations of enzymes and
xenobiotic substrates ever occur, for the “P450cam type
logic” to be of any functional significance. Further, in
our lab studies, we couldn’t note any significant spectral
change (a hypsochromic shift of Soret spectra or the
emergence of the high spin signature band at 650 nm)
for some CYPs that we checked (CYP2C9-Diclofenac
and CYP2E1-Chlorzoxazone; at micromolar level of the
enzyme and a ligand pressure of 1:100). Also, it is diffi-
cult to imagine that diverse molecules of varying topog-
raphy and electrostatics could bind efficiently to the very
same loci in the distal pocket or near the channel to be
transported to the distal site. A simple pictorial under-
standing of the erstwhile paradigm is shown in Fig. 2.
The erstwhile hypothesis requires that in the transition
state, the heme-Fe-O species is within bonding distance
of both C and H atoms of the substrate. In the extensive
dockings we carried out and from several crystal struc-
tures of CYPs available till date, one cannot find any evi-
dence for this requisite. On the other hand, if approach
or binding of substrate to a protein surface or crypt
served as a molecular trigger [as seen in the well-known
and explicable example of some lipases where a flap
opens up upon the presence of a hydrophobic substrate
(Grochulski et al. 1993)], then the different loci for di-
verse substrate binding should be mobile and engineered
to swing around and position the bound substrate at
heme centre. Quite simply, this is asking for too much
“intelligence” from a simple protein molecule. We
indulged even this proposition but could not find any
evidence to this effect (Tables 2 and 3). Further, the data
from sections 8 through 10 of results presented above
Fig. 2 The erstwhile mechanism of binding of substrate at a distinct locus (distant from heme centre) and oxygen rebound at heme centre: The
erstwhile mechanism seeks (i) binding of the substrate to the heme distal pocket, (ii) the generation of a localized two-electron deficient reactive
intermediate at the heme centre, (iii) transposition/translocation of the substrate within bonding distance in the transition state and (iv) dissociation of
the product and outward diffusion of the same owing to lower binding affinity (after the completion of reaction)
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give very convincing arguments against the erstwhile
hypothesis.
We propose the following probabilistic phenomeno-
logical hypothesis, which not only explains most of the
experimental observations and in silico findings, but also
justifies Occam’s razor’s criteria. (This is, albeit, at the
aesthetic expense of tolerating a “radical” hypothesis.)
The essential aspects of the ‘radical’ hypothesis, which is
already introduced in our earlier works, (Gideon et al.
2012; Manoj et al. 2010a; Manoj et al. 2010b; Parashar et
al. 2014) are as follows- CPR produces diffusible species
that serve as one-electron equivalents (like superoxide),
which bind with CYP and get stabilized. These catalytic
species (whether bound or free) thereafter convert the
substrates. In this hypothesis, the heme centre can be re-
duced or activated in three different ways-
(i.)One-electron equivalents generated by CPR can be
relayed to the heme centre through diffusible
species, via the proximal thiolate (and a molecule of
oxygen could subsequently bind to the distal heme
centre). A survey of the prominent microsomal
CYPs shows that all these enzymes have a readily
solvent accessible proximal site (Additional file 1A,
Figure A1P), which makes this process very facile.
(ii.)The presence of a suitable substrate could reduce
the heme centre on its own merit (and a molecule
of oxygen could subsequently bind to the distal
heme centre).
(iii.)Superoxide or hydroxyl radicals generated in situ
could bind to the distal heme centre by diffusion
through the distal channel.
The outcomes of all the three steps above would be
the same. Thus, if we indulged a hypothesis that the
hydrophobic distal pocket of CYP hemes could serve as
“a residence/stabilization zone” for reactive species (like
hydroxyl or superoxide radicals), then the functional life-
time of the same increases significantly. This supposition
is justified by a pioneering paper published in the late
1970s (Blumenthal and Kassner 1979). While probing
the binding of azide to a model hemoprotein, they had
concluded that enhanced polarity of the heme distal
pocket confers oxygen binding (and auto-oxidation of
heme) whereas the anion binding and its stabilization is
favored in the hydrophobic heme pockets. Therefore, if
the CYP is not present in the vicinity to stabilize the dif-
fusible reactive species, the one-electron equivalents dif-
fuse out into the aqueous phase and are lost to water
formation. If CYPs are present and if the substrate is
bound on the surface (or even the heme distal pocket or
any other crypts therein) of the CYP and available nearby,
the probability of reaction goes up very highly. The rate
enhancement is neither through a one site “lock & key”
mechanism (alone) nor through an “induced fit”. The en-
zyme enhances rates by stabilizing the diffusible reactive
intermediate and by enhancing the probability of the
reactive intermediate to find the substrate in/around its
vicinity. Therefore, there exists a definite “uncertainty”
with respect to the exact locus of interaction of the sub-
strate and reactive intermediate. To the best of our know-
ledge, such a way of enzyme functioning is not yet
advocated. Therefore, we coin our proposal as ‘murburn’
hypothesis (“mured burning”- connoting a mild and unre-
strained burning in a confined microenvironment) and
such macromolecules as murzymes (mediating unre-
strained redox catalysis). The representation in Fig. 3 cap-
tures the essential scheme for interaction of various
xenobiotic substrates with CYPs. In comparison with the
erstwhile hypothesis (shown in Fig. 2), the new hypothesis
does not seek a high affinity binding or translocation into
the deep-seated heme pocket for a direct heme Fe-O to
drug molecule bond formation step. Nanomolar con-
centrations of diffusible radicals could be envisaged to
have effective diffusion radius of several Angstroms
(even up to nano-scales), given the hydrophobic pocket
of CYPs. The reaction mediated in such a scenario can
be nonspecific or regiospecific and even be enantiose-
lective. The case must be noted that most CYPs
hydroxylate diverse drugs at the most energetically
Fig. 3 Interactions of various xenobiotics and DROS with microsomal
CYPs: There are distinct binding sites for the two substrates (DROS and
xenobiotics) and these loci are not brought together by an induced fit,
for a direct bond-formation (between the two substrates) in the
transition state. There exists an uncertainty regarding the exact
locus where the two substrates finally interact/react, as a probabilistic fate
governs the outcome. The xenobiotic substrate 4 could go through the
oxidation at/near the heme centre and such reactions would be favored
at high enzyme:ligand concentrations/ratios. Other substrates would
have better probability of being reacted by the given CYP away from
the heme centre. This may be owing to better binding per se (as in
substrate 1) or/and because of a more probable presentation to the
reactive species as it emerges out from the distal heme pocket (as in
substrate 3). The reactivity of a molecule like two would be dependent
on several factors
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favorable loci within the substrate molecule (and not
the most spatially open centre). This specificity can also
be achieved in suitable chemical controls in enzyme
reactions that involve diffusible species ((Manoj 2006)
and our unpublished work). Also, if the hydroxyl moi-
ety incorporation was completed in the heme distal
pocket at the heme centre, then we cannot explain how
a bevy of substrates get activated by additives (Hutzler
et al. 2001; Kenworthy et al. 1999) or why some
substrates are not metabolized by some CYPs. Multiple
molecules binding at the heme centre in a dynamic
state would be a low probability event (though one gets
crystal structures of these types of complexes from
highly concentrated systems). We have already ex-
plained these findings for heme-peroxidases (Andrew et
al. 2011; Gade et al. 2012; Parashar and Manoj 2012)
and the same explanations could hold well here too.
Application of ‘murburn’ hypothesis to explain kinetics
and mechanism
If we continue with the discussion on the Michaelis-
Menten supposition (from the earlier section above)-
KM ¼ k−1 þ k2ð Þ = k1ð Þ ð1Þ
As per laws of equilibrium-
Kd ¼ k−1ð Þ= k1ð Þ ð2Þ
It is clear that-
KM ¼ Kd þ k2=k1ð Þ ð3Þ
Therefore,
KMe Kd; when k−1 >> k2 ð4Þ
and/or
KMe Kd; when k2=k1ð Þ ¼ 0 ð5Þ
Now, the erstwhile hypothesis assumes that once the
substrate is hydroxylated, it loses efficiency for the
enzyme. Therefore, the forward breakdown of EP may
be comparable or efficient with respect to the backward
breakdown of ES. In this case, the contribution of k2
cannot be neglected. Therefore, we might have a higher
value of KM than that of Kd. But under any circum-
stances, the value of KM cannot be lower than that of
Kd. If one were to accept the ideas advocated by
Guengerich group, most microsomal P450-substrate
forward binding is very fast and only diffusion limited
(k1 ~ 10
9 M−1 s−1). If that were true, it is highly unlikely
that the physical value of k2 can approach k1 and there-
fore, supposition (e) tends to be the applicable scenario
(as is true for many enzymes in normal environments).
Under such scenarios, the data in Table 20 cannot be
explained by the erstwhile hypothesis. The new hypothesis
offers the following reasons for the same-
1. Experimental KM: It is a reflection of multiple
events: (a) binding of substrate with enzyme, (b)
production and binding of diffusible radicals with
heme centre, (c) reaction of diffusible radicals with
substrate & (d) competition of half-reacted substrate
(intermediates) with other reactive species within
milieu. If we imagine such a scenario, we can explain
the poor correlation of Kd and KM. With the new
hypothesis, we can also account for the changes in
KM values under various setups of the same CYP
and substrate combination.
2. Conversion time: It is an index of the overall
processes listed in 1 above. It is not an index of
“committed to catalysis” or binding of substrate to
heme pocket at all.
[Besides the above, there could be systemic errors in
the protocols employed in P450 research with- a. Experi-
mental Kd determination by Soret differential spectrum:
The Type I binding could be mistaken for heme reduc-
tion, both of which are associated with a similar Soret
change. (Only the high spin marker at 650 nm is conclu-
sive of Type I binding associated spin shifts for FeIII
heme thiolates.) Further, the binding of hundreds of mi-
cromolar substrates to micromolar enzyme is not a good
measure of the reaction environment (wherein, nM
levels of CYPs have very little probability to bind to mi-
cromolar levels of substrates). b. Experimental Kd deter-
mination by equilibrium dialysis: Non specific bindings
on to microsomal and other membranes would give
higher values. c. In silico Kd determination by heme
pocket centered docking: Binding of a small organic
molecule with a hydrophobic pocket gives similar ΔG
values for a bevy of substrates and non-substrates with
CYPs. This binding cannot be taken as an index of
substrate’s affinity to the heme pocket. In many cases,
actual access to the cavity may not be available on the
kinetically relevant time scale.]
Our study implies that binding and reaction of the
substrate at the heme-centre [as exemplified and sought
by oxygen rebound from Compound I, (Groves 1985)]
may not be an obligatory requirement for many CYPs-
substrates combinations. (However, the study does not
rule out the possibility either. Particularly, at high con-
centrations of enzymes (more than micromolar levels)
and substrates (hundreds of micromolar levels), heme
pocket binding of small molecules would be a relatively
high probability event (Parashar et al. 2014). We would
also like to add a disclaimer here that the hydrogen atom
abstraction mechanism is not being challenged.) One
wonders how the constrained and hydrophobic distal
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sites of CYPs afford an efficient proton shuttle in the
phospholipid microenvironment. The pKa of the sub-
strate’s alkyl/aromatic hydrogens are way higher to be of
any relevance (and that of the corresponding product’s
hydroxyl protons are several units higher than reaction
pH). The physiological/reaction pH affords protons at a
meagre concentration of only ~40 nM. An analysis of
the active site and cavities/channels of microsomal
CYPs shows clearly that this requirement sought by the
erstwhile paradigm is stretching Occam’s razor criteria
(Tables 2 and 3). Based on our works till date, the reac-
tion scheme of the CYP + CPR system could be minim-
ally represented now as-
2O2 þ NAD Pð ÞH→ 2O2−
þ NAD Pð Þþ þ Hþ Primarily; CPR’s roleð Þ
ð6Þ
RX þ O2− þ Hþ→ ROH
þ OX Primarily; CYP0s = milieu’s rolesð Þ
ð7Þ
O2
−= OX þ O2−=OX=RH = OH−= NAD Pð ÞH
= H2O2= Enzymes→ Diverse fatesð Þ
ð8Þ
RX þ O2 þ NAD Pð ÞH→ ROH
þ NAD Pð Þþ þ OX− Overallð Þ
ð9Þ
The first three equations depict the essential initiation
process and the multiple competitions at later stages.
Now, we can understand why experimentally determined
KM values show wide variations across reaction setups.
The interaction of reactive species with the substrate is
not captured or limited to its (substrate’s) binding of
CYP at a particular site, but is more about its presenta-
tion in the relatively complex reaction scheme. The
overall equation (9) shows the macroscopic thermo-
dynamic drive at the phospholipid interface. That is- the
uncharged hydrophobic molecules react to give ionic
and hydrophilic species. This eventuality, in turn, serves
as driving force for inundation and washing away by
water molecules. As seen from equation (9), the system
does not require extraneous protons. Till date, there ex-
ists no evidence for the consumption of a solvent proton
at the heme centre. There is only proof for the incorpor-
ation of extraneous hydrogen atom into the substrate
and this step need not occur at the heme centre in
CYPs. CPR’s activity generates protons and radicals in
the microenvironment. CYPs stabilize radicals generated
and the event of oxygen and/or hydrogen atom insertion
into the substrate could occur even outside the heme
distal pocket. The rapid reactions of radical species
would serve to pull the redox equilibrium to the right,
and this is achieved by substrate oxidation (more effi-
cient) or depletion of ROS (less efficient). The process is
essentially constitutive and the coinage of murburn hy-
pothesis signifies the radical process involving oxygen in
the vicinity of heme (or other such redox) enzymes. The
relevance of such a process in liver cells (and within cel-
lular membrane interfaces in general) and its mandate in
evolution needs to be probed further. Most importantly,
the hypothesis makes a lot of kinetic sense. At an in-
stance, nM levels of CYP/CPR could stabilize suprana-
nomolar levels of highly mobile ROS/radicals within
milieu (and this process is not ordered). The reaction of
these intermediates with micromolar levels of drug mol-
ecules can explain the overall kinetics.
The new hypothesis is not countered by the fact that
mutations of key amino acids in the heme distal pocket
could deleteriously or positively affect activity (Butler et
al. 2013; Hamdane et al. 2008; de Montellano 2015).
This effect need not be brought about by substrate-
binding alone, but it can also be owing to altered ROS
dynamics (Gideon et al. 2012). If we could think of “out
of the active site” solutions to explain the phenomen-
ology of CYP reaction chemistry, there is ample scope
for the murburn concept to explain most aspects of CYP
reactivity. Very importantly, the new hypothesis justifies
several key mechanistic findings and proposals from
Hollenberg’s and Newcomb’s groups (Lin et al. 2012;
Zhang et al. 2011; Zhang et al. 2013; Sheng et al. 2009;
Newcomb et al. 2003a; Newcomb et al. 2003b),
regarding-
(i.)mechanism-based inactivations: It was observed that
loss of activity resulted owing to the covalent
modifications of CYPs’ surface amino acid residues,
by substrate molecules like Bergamottin,
Clopidogrel, ethynylphenanthrene etc. and
(ii.)presence of multiple electrophilic reactive species in
the CYP reaction milieu.
The new hypothesis could justify the KIEs and LFEs
obtained in several P450 reactions. A substrate bound
on a surface crypt or even freely tumbling around near
the enzyme could be subjected to catalysis by a diffusible
reactive intermediate. The propensity and differentiated
reactivity of very low amounts of this agent’s interaction
with various moieties of a substrate could explain the
extrinsic and intrinsic KIEs (Manchester et al. 1997) and
provides room for multiple reactant species (Newcomb
et al. 2003b; Coon 2003), which address concerns like-
“the Fe-Oxo species does not have the required potential
to activate some substrates”. Further, the new concept
affords a greater scope for explaining the activation/in-
hibition of substrate catalysis by diverse additives. The
new hypothesis can also explain how constrained loci of
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the substrate molecules could get hydroxylated when
more open carbon atoms are left untouched by the
highly reactive intermediate. Depiction of the overall
topographies and distal surfaces of the major CYPs are
shown in Figure A1Q of Additional file 1A. CYP3A4,
with three channels and a large heme distal pocket is the
most proficient of all CYPs (followed by CYP2D6 and
CYP2C9) (as seen in Fig. 4). Coupled with its highly
hydrophobic surface (to which diverse xenobiotic sub-
strates can transiently bind) adjacent to the channel
openings, the probability of the reactive intermediate
meeting a substrate molecule in the vicinity of the distal
pocket goes up significantly. (The large volume of
CYP3A4’s distal pocket is not enough to explain its
versatility because CYP2C9 also has a comparable
hydrophobic voluminous pocket. CYP2D6 (with a rela-
tively straight and wide channel) could allow small
molecules’ enantioselective oxidations within the distal
pocket, as is seen for benzylic hydroxylation of bufuralol.
CYP2E1, without a channel that leads to the distal
pocket, is a special case. It can be seen that this system
has excess accumulation of ROS species and obligatorily
requires Cyt. b5. (This scenario is akin to P450cam need-
ing putidaredoxin for effective activity. This may be be-
cause the probability for the ROS to bind at the heme
centre via distal side goes down significantly.) Perhaps,
the proximal side could also be involved in some reac-
tion modalities. A specific antibody knocks out a given
CYP’s activity because the antibody would bind to the
surface region where the substrate would preferably
bind. A strongly Type II binding substrate (which shows
similar in silico and X-ray structures; like the large
azoles) could potentially bind effectively to the heme
centre with F & G loop opening at high enzyme-
inhibitor concentration. Otherwise, they would be effi-
ciently metabolized by CYPs because the probability of
heme access of a large molecule would be lower when
compared to their metabolism outside (Andrew et al.
Fig. 4 Visualization of channels leading to the distal pocket in the major CYPs (from the distal surface). The first two rows have the distal view
with the heme falling on the plane of the paper and the images have been rendered 20 % transparent, to show the position of the deep seated
heme (in deep blue). The highly continuous hydrophobic helices have been marked red. Further, an amino acid lining the access channel (if any)
is also marked. The lower rows show the structures of the major CYPs. The amino acids marked with green are salient ones that mark the entry
to the channel(s) leading to the distal pocket, as seen from different angles. In these images, the heme can be visualized through the channel, as
yellow stick frames
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2011; Manoj 2006; Manoj and Hager 2008). This is the
reason why a molecule like Itraconazole is metabolized
by CYP3A4. The pseudohyperbolic asymptotes (hitherto
taken as Michaelis-Menten curves) are an index of the
reactive intermediate’s interaction with the substrate.
Depending on the reaction microenvironment (partition-
ing effects) and redox status therein, the curves can be
affected significantly. This is why lipids, CPR/Cyt. b5
amounts etc. can alter the values of the pseudo KM ob-
tained. The very low Ki values obtained at times are an
index of the radical formation and stabilization at low
concentrations of the enzyme/additive. Larger molecules
needn’t get into the distal pocket the through narrow or
non-existent channels. Earlier, it was difficult to answer
the question: Why is it that a given highly reactive inter-
mediate of a promiscuous CYP (which could accommo-
date a given or several small molecule(s) in its active
site) not observed to experimentally catalyze the given
small molecule substrate? Now, it is understood that
binding at an alternate and more topologically preferred
location would be needed to enhance the probability of
the substrate meeting the reactive diffusible intermedi-
ate. Protons are not needed at the heme centre with the
new hypothesis. Hydroxylations caused by a diffusible
radical species tend to be non-enantioselective and non-
regiospecific. Both scenarios can change if the radical
catches a bound substrate in a particular enantiotopic
presentation, while it emerges from the heme centre or
if the substrate is small enough and could gather signifi-
cant access into the distal channel. The kinetic prefer-
ence of a particular substrate enantiomer (without
affording enantioselectivity of the product) is perfectly
agreeable with the new hypothesis. Reactivity of the mol-
ecules themselves and presentations within or outside
the heme distal pockets could be reasons for differences
in activity within a given class of drug molecules. Most
importantly, drug-drug interactions and genetic predis-
position to drugs can be better explained by the new hy-
pothesis. Also, since the new perception does not solicit
a tight binding, products could be further oxidized with-
out the necessity of being bound within the heme distal
pocket.
Projections to ratify the new hypothesis
1. A simple way to positively test the murburn hypoth-
esis is to look for reactivity of several CYPs towards a
non-substrate with the introduction of a substrate (of
suitable redox potential) and vice-versa (and noting en-
hancement/inhibition if any). That is- a non-substrate
could get converted if a suitable substrate is added into
milieu. The activity towards a substrate could go up or
get lowered if a non-substrate is introduced into milieu.
The newly proposed hypothesis predicts a two step, one-
electron route (whereas the erstwhile hypothesis is
supposed to proceed via a single step, two-electron
route) and workers should be able to ratify our predic-
tion upon suitable selection of the CYP/substrate/modu-
lator and tailoring of reaction environment. 2. Another
way to test for the new hypothesis (or negate the erst-
while hypothesis) is- Small drug molecules that do not
serve as “naturally” functional substrates could be pre-
sented to CYPs (for example- Chlorzoxazone to CYP2C9
and Flurbiprofen to CYP2E1) and the proteins allowed
to crystallize. If we obtain crystals of the protein with
the “non-substrate” drug molecule within the hydropho-
bic pocket, it must mean that this CYP structure (and
the processes that led the substrate docking at the
hydrophobic distal pocket) has little functional signifi-
cance. 3. Enantiomeric excess, yield/specificity and prod-
uct formation rates could be studied for a variety of
molecules (with both activated and non-activated carbon
as reaction centres; keeping the functionality of the react-
ive moiety constant) by- (a) increasing size of the molecule
by substitutions away from the reaction centre (to probe
the general diffusion constraints) & (b) introducing substi-
tutions adjacent to the reactive centre (to see if reactivity
occurs at the heme floor)- to give insights on the uncer-
tainties involved. 4. The murburn hypothesis seeks obliga-
tory role of diffusible radicals and ROS in the reaction
scheme. Therefore, we should observe- (i) a temporal
change in reaction stoichiometry/coupling (dynamics of
ROS and competitions thereof) by varying the reaction
components’ compositions/concentrations. (ii) Suitable
one-electron scavenging small molecules, ions or enzymes
should possess the ability to modulate/inhibit CYP/CPR
reactions. (iii) It should be possible to experimentally
simulate CYP reactions without CPR complexations (with
ROS species alone or with non-specific redox partners
and substrates). (iv) It should be possible to approach the
reaction paradigm in CYP chemistry with suitable chem-
ical controls. Also, chemical (non-enzymatic) controls
should give enhanced specificity/rates upon reaction sys-
tem modification (along the lines shown in Manoj 2006)
for the hydroxylation reaction. 5. Modulations of reaction
outcome/efficiency may be noted to various levels by
changing the concentrations of CYPs/CPR and other
small molecule redox-active additives (by virtue of affect-
ing the competing reactions). 6. Most importantly- the
erstwhile theory solicits that substrate binding to CYP is
obligatorily required for the latter to receive electrons
from CPR, leading to activation of molecular oxygen at
heme centre. This supposition could be tested with simple
reaction controls lacking the substrate (in diverse CYP-
substrate setups) and checking for ROS in milieu.
Conclusions
We have already demonstrated earlier that catalysis
mediated by enzyme sponsored diffusible species can be
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very specific (regarding the preference of substrates, lo-
cation of action within the substrate etc.) and projected
the importance of the same (Manoj 2006). In those reac-
tions also, the reactivity was afforded at the most ener-
getically favored locus, quite akin to CYPs. So, it is seen
that the CPO model is quite relevant to CYPs, in terms
of some aspects of the overall phenomenology. Now,
ROS in CYP reactions need not be seen as a result of an
inefficient enzyme or inefficient substrate (or their com-
bination, together with “badly chosen” or “unoptimized”
reaction parameters) alone. Earlier, the binding of sub-
strate molecules within the active site was supposed to
account for and/or prevent such eventualities. This is
now seen to be a redundant concept. The liver micro-
somes have no way of getting to know what substrates
they would meet. So, the evolutionary agenda is ad-
dressed by the combination of CYP-CPR-NADPH-dira-
dical oxygen (in lipid microenvironment). Herein, we
have provided meta-analyses, arguments and extensive
‘in silico’ findings based on currently available docking
programs (which use scoring functions for spatial com-
plementarities, electrostatics/molecular force fields) to
support the deductions that-
(1)Well-defined spatio-temporal constraints are not
very evident in several CYP reactions. This finding is
highly unlike a phenomenon occurring at occluded cen-
tres such as the heme distal site. Therefore, the heme
distal pocket may be relatively passive in ‘interactions’
with several xenobiotic substrates. (2) The newly pro-
posed murburn hypothesis explains key experimental
and theoretical aspects of CYP reaction system.
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